Deformable polymers comprising fixed primers
By using deformable polymers to change volume under physical or chemical triggering, the positional changes of fixed primers can be achieved, solving the problem of low sequencing efficiency of the forward and reverse strands in existing technologies, and improving the efficiency and throughput of nucleic acid sequencing.
Patent Information
- Application Number
- CN202380030503.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-08-11
- Filing Date
- 2023-09-18
- Publication Date
- 2024-11-12
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing technologies have low efficiency, throughput, and speed in sequencing forward and reverse strands, especially when self-hybridization structures are formed, making efficient sequencing difficult.
By using deformable polymers, their volume can be expanded or contracted through physical or chemical triggering, thereby changing the position of fixed primers and enabling selective processing and concurrent sequencing of polynucleotide sequences.
It improves the efficiency and throughput of nucleic acid sequencing, enabling efficient sequencing of both forward and reverse strands simultaneously, while reducing sequencing time and cost.
Smart Images

Figure CN118946668A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to deformable polymers comprising immobilized primers, in particular for use in nucleic acid sequencing, such as concurrent sequencing. Background Art
[0002] In some types of next generation sequencing (NGS) technologies, nucleic acid clusters are generated on a flow cell by amplifying an initial template nucleic acid strand. Sequencing cycles can be performed while synthesizing a complementary strand of the template nucleic acid, i.e., using a sequencing-by-synthesis (SBS) approach.
[0003] In each sequencing cycle, a deoxyribonucleic acid analog conjugated to a fluorescent marker is hybridized with a template nucleic acid, and an excitation light source is used to excite the fluorescent marker on the deoxyribonucleic acid analog. The detector captures the fluorescent emission of the fluorescent marker and identifies the deoxyribonucleic acid analog. Therefore, the sequence of the template nucleic acid can be determined by repeatedly performing such sequencing cycles.
[0004] NGS allows the sequencing of many different template nucleic acids simultaneously, which has significantly reduced the cost of sequencing over the past two decades.
[0005] One difficulty is sequencing the forward and reverse strands (or the forward and forward complement strands, or the reverse and reverse complement strands) because these strands have a tendency to form self-hybridization structures. Current methods typically first sequence the forward strand in the absence of the reverse strand (e.g., by removing the reverse strand), resynthesize the reverse strand and remove the forward strand, and then sequence the reverse strand in the absence of the forward strand.
[0006] However, it remains desirable to develop new sequencing strategies, particularly for greater efficiency, throughput, and speed. Summary of the invention
[0007] According to one aspect of the present invention, there is provided a deformable polymer, the deformable polymer comprising:
[0008] a first plurality of immobilized primers; and
[0009] a plurality of second fixed primers,
[0010] wherein the plurality of first fixed primers and the plurality of second fixed primers occupy a first set of positions on the deformable polymer,
[0011] Wherein the deformable polymer is configured such that when the deformable polymer is exposed to a deformation trigger, the plurality of first fixed primers and the second fixed primers are shifted to a second set of positions on the deformable polymer that is different from the first set of positions.
[0012] According to one aspect of the present invention, there is provided a material composition, the material composition comprising:
[0013] polymers capable of deformation;
[0014] a first plurality of immobilized primers; and
[0015] a plurality of second fixed primers,
[0016] wherein the plurality of first fixed primers and the plurality of second fixed primers occupy a first set of positions on the deformable polymer,
[0017] Wherein the composition is configured such that when the deformable polymer is exposed to a deformation trigger, the plurality of first immobilized primers and the second immobilized primers are translocated to a second set of locations on the deformable polymer that is different from the first set of locations.
[0018] In one aspect, the deformation trigger causes a volume expansion of the deformable polymer.
[0019] In one aspect, the expansion is an increase in volume of at least 20%.
[0020] In one aspect, the expansion is an increase in volume of at least 50%.
[0021] In one aspect, the expansion is an increase in volume of at least 100%.
[0022] In one aspect, the deformation trigger causes a volume contraction of the deformable polymer.
[0023] In one aspect, the shrinkage is a reduction in volume of at least 20%.
[0024] In one aspect, the shrinkage is a reduction in volume of at least 50%.
[0025] In one aspect, the shrinkage is a reduction in volume of at least 100%.
[0026] In one aspect, the deformation trigger causes shuffling of the first and second immobilized primers.
[0027] In one aspect, the reorganization is accompanied by a 20% volume reduction to a 20% volume increase of the deformable polymer.
[0028] In one aspect, the reorganization is accompanied by a 10% volume reduction to a 10% volume increase of the deformable polymer.
[0029] In one aspect, the reorganization is accompanied by a 5% volume reduction to a 5% volume increase of the deformable polymer.
[0030] In one aspect, the deformation trigger is a physical trigger and / or a (bio)chemical trigger.
[0031] In one aspect, the physical trigger comprises a temperature change of the deformable polymer.
[0032] In one aspect, the (bio)chemical trigger comprises a change in salt concentration.
[0033] In one aspect, the (bio)chemical trigger comprises a pH change.
[0034] In one aspect, the first immobilized primer and / or the second immobilized primer is attached to the deformable polymer via a covalent bond.
[0035] In one aspect, the covalent bonds include cycloadducts, alkenylene bonds, esters, amides, acetals, hemiaminal ethers, aminals, imines, hydrazones, sulfide bonds, boron-based bonds, silicon-based bonds, or phosphorus-based bonds.
[0036] In one aspect, the cycloadduct comprises a 1,2,3-triazole linkage.
[0037] In one aspect, the deformable polymer is comprised of a plurality of particles.
[0038] In one aspect, the particles are nanoparticles.
[0039] In one aspect, the deformable polymer is a hydrogel.
[0040] In one aspect, the deformable polymer is formed from acrylamide-based monomers.
[0041] According to another aspect of the present invention, there is provided a solid support comprising a deformable polymer as described herein.
[0042] In one aspect, the solid support is a flow cell.
[0043] According to another aspect of the present invention, a kit is provided, the kit comprising the deformable polymer as described herein or the solid carrier as described herein.
[0044] According to another aspect of the present invention, there is provided use of the deformable polymer as described herein or the solid support as described herein in nucleic acid sequencing.
[0045] According to another aspect of the present invention, there is provided a method for manufacturing a deformable polymer, the method comprising:
[0046] (a) fixing a plurality of first precursor primers to a deformable polymer to form a plurality of first fixed primers; and
[0047] (b) immobilizing a plurality of second precursor primers to the deformable polymer to form a plurality of second immobilized primers;
[0048] Wherein the deformable polymer is configured such that when the deformable polymer is exposed to a deformation trigger, the plurality of first fixed primers and the second fixed primers are shifted to a second set of positions on the deformable polymer that is different from the first set of positions.
[0049] In one aspect, step (a) and step (b) are performed sequentially or simultaneously.
[0050] In one aspect, step (b) is performed after step (a).
[0051] In one aspect, step (a) is performed after step (b).
[0052] In one aspect, step (a) and step (b) are performed simultaneously.
[0053] In one aspect, immobilizing comprises forming covalent bonds between the solid support and each first precursor primer in the plurality of first precursor primers and between the solid support and each second precursor primer in the plurality of second precursor primers.
[0054] In one aspect, forming the covalent bond involves using a click reaction.
[0055] In one aspect, forming a covalent bond involves forming a 1,2,3-triazole bond.
[0056] According to another aspect of the present invention, there is provided a method for preparing a polynucleotide sequence for identification, the method comprising:
[0057] (a) providing a deformable polymer as described herein;
[0058] (b) synthesizing at least one first polynucleotide sequence and at least one second polynucleotide sequence, wherein the at least one first polynucleotide sequence each comprises a first portion and each extends from a first fixed primer, and the at least one second polynucleotide sequence each comprises a second portion and each extends from a second fixed primer, wherein the second polynucleotide sequence is substantially complementary to the first polynucleotide sequence.
[0059] In one aspect, the method further comprises the steps of:
[0060] (c) exposing the deformable polymer to a deformation trigger.
[0061] In one aspect, the deformation trigger causes expansion of the deformable polymer.
[0062] In one aspect, the deformation trigger causes contraction of the deformable polymer.
[0063] In one aspect, the deformation trigger causes expansion and then contraction of the deformable polymer, or contraction and then expansion of the deformable polymer.
[0064] In one aspect, the deformation trigger is a physical trigger and / or a (bio)chemical trigger.
[0065] In one aspect, the physical trigger comprises a temperature change of the deformable polymer.
[0066] In one aspect, the (bio)chemical trigger comprises a change in salt concentration.
[0067] In one aspect, the (bio)chemical trigger comprises a pH change.
[0068] In one aspect, the method further comprises the step of preparing the first portion and the second portion for concurrent sequencing.
[0069] In one aspect, the method comprises simultaneously contacting a first sequencing primer binding site located after the 3' end of the first portion with a first primer and contacting a second sequencing primer binding site located after the 3' end of the second portion with a second primer.
[0070] In one aspect, the method further comprises the step of processing at least one first polynucleotide sequence comprising a first portion and at least one second polynucleotide sequence comprising a second portion such that a proportion of the first portion is capable of generating a first signal and a proportion of the second portion is capable of generating a second signal.
[0071] In one aspect, the processing involves selective processing to cause the strength of the first signal to be greater than the strength of the second signal.
[0072] In one aspect, the concentration of the first moiety capable of generating a first signal is greater than the concentration of the second moiety capable of generating a second signal.
[0073] In one aspect, the ratio between the concentration of the first moiety capable of generating the first signal and the concentration of the second moiety capable of generating the second signal is between 1.25:1 and 5:1.
[0074] In one aspect, the ratio is between 1.5:1 and 3:1.
[0075] In one aspect, the ratio is about 2:1.
[0076] In one aspect, selective processing comprises preparing for selective sequencing or performing selective sequencing.
[0077] In one aspect, the selective processing comprises performing selective amplification.
[0078] In one aspect, the selective treatment comprises contacting a first sequencing primer binding site located after the 3′ end of the first portion with a first primer, and contacting a second sequencing primer binding site located after the 3′ end of the second portion with a second primer, wherein the second primers comprise a mixture of blocked second primers and unblocked second primers.
[0079] In one aspect, the blocked second primer comprises a blocking group at its 3' end.
[0080] In one aspect, the capping group is selected from the group consisting of a hairpin loop, a deoxynucleotide, a deoxyribonucleotide, a hydrogen atom replacing a 3'-OH group, a phosphate group, a phosphorothioate group, a propyl spacer, a modification that caps the 3'-hydroxyl group, or an inverted nucleobase.
[0081] In one aspect, the selective treatment comprises selectively removing some or substantially all of the second fixed primers that have not been extended, and performing further amplification cycles to selectively amplify the first polynucleotide sequence relative to the second polynucleotide sequence.
[0082] In one aspect, the selective treatment comprises selectively blocking some or substantially all of the second fixed primers that have not yet been extended using a primer blocking agent, wherein the primer blocking agent is constructed to limit or prevent the synthesis of a chain extending from the second fixed primer, and the selective treatment is subjected to further amplification cycles to selectively amplify the first polynucleotide sequence relative to the second polynucleotide sequence.
[0083] In one aspect, the primer blocking agent is added while the first polynucleotide sequence is hybridized to the second immobilized primer.
[0084] In one aspect, the method comprises contacting some or substantially all of the second fixed primers with an extension primer sequence, wherein the extension primer sequence is substantially complementary to the second fixed primer and further comprises an additional 5′ nucleotide; and adding the primer blocking agent, wherein the primer blocking agent is complementary to the additional 5′ nucleotide.
[0085] In one aspect, the primer blocking agent is a blocked nucleotide.
[0086] In one aspect, the blocked nucleotide comprises a blocking group at its 3' end.
[0087] In one aspect, the capping group is selected from the group consisting of a hairpin loop, a deoxynucleotide, a deoxyribonucleotide, a hydrogen atom replacing a 3'-OH group, a phosphate group, a phosphorothioate group, a propyl spacer, a modification that caps the 3'-hydroxyl group, or an inverted nucleobase.
[0088] In one aspect, the blocking nucleotide is A or G.
[0089] In one aspect, the first signal and the second signal are spatially resolved.
[0090] In one aspect, the first signal and the second signal cannot be spatially resolved.
[0091] According to another aspect of the present invention, there is provided a method for sequencing a polynucleotide sequence, the method comprising:
[0092] Prepare polynucleotide sequences for identification using methods described herein; and
[0093] The nucleobases in the first and second parts are sequenced.
[0094] In one aspect, the step of sequencing the nucleobases in the first portion and the second portion involves concurrently sequencing the nucleobases in the first portion and the second portion.
[0095] In one aspect, the step of sequencing the nucleobases comprises performing sequencing by synthesis or sequencing by ligation.
[0096] In one aspect, the method further comprises the step of performing paired-end reads.
[0097] In one aspect, the step of concurrently sequencing nucleobases comprises:
[0098] (a) obtaining first intensity data, the first intensity data comprising a combined intensity of a first signal component obtained based on a corresponding first nucleobase at a first portion and a second signal component obtained based on a corresponding second nucleobase at a second portion, wherein the first signal component and the second signal component are obtained simultaneously;
[0099] (b) obtaining second intensity data, the second intensity data comprising a combined intensity of a third signal component obtained based on the corresponding first nucleobase at the first portion and a fourth signal component obtained based on the corresponding second nucleobase at the second portion, wherein the third signal component and the fourth signal component are obtained simultaneously;
[0100] (c) selecting one of a plurality of categories based on the first intensity data and the second intensity data, wherein each category represents a possible combination of a corresponding first nucleobase and a corresponding second nucleobase; and
[0101] (d) base calling the corresponding first nucleobase and the corresponding second nucleobase based on the selected classification.
[0102] In one aspect, selecting the classification based on the first intensity data and the second intensity data includes selecting the classification based on a combined intensity of the first signal component and the second signal component and a combined intensity of the third signal component and the fourth signal component.
[0103] In one aspect, the plurality of categories comprises sixteen categories, each category representing one of sixteen unique combinations of a first nucleobase and a second nucleobase.
[0104] In one aspect, the first, second, third, and fourth signal components are generated based on light emissions associated with respective nucleobases.
[0105] In one aspect, the light emission is detected by a sensor, wherein the sensor is configured to provide a single output based on the first signal and the second signal.
[0106] In one aspect, the sensor includes a single sensing element.
[0107] In one aspect, the method further comprises repeating steps (a) through (d) for each base calling cycle in a plurality of base calling cycles.
[0108] According to another aspect of the present invention, a kit is provided, the kit comprising instructions for preparing a polynucleotide sequence for identification as described herein and / or for sequencing a polynucleotide sequence as described herein.
[0109] According to another aspect of the present invention, there is provided a data processing device comprising means for executing the method as described herein.
[0110] In one aspect, the data processing device is a polynucleotide sequencer.
[0111] According to another aspect of the present invention, there is provided a computer program product, the computer program product comprising instructions, which, when the program is executed by a processor, cause the processor to perform the method as described herein.
[0112] According to another aspect of the present invention, a computer-readable storage medium is provided. The computer-readable storage medium includes instructions. When the instructions are executed by a processor, the processor is caused to perform the method as described herein.
[0113] According to another aspect of the present invention, a computer readable data carrier is provided, on which a computer program product as described herein is stored.
[0114] According to another aspect of the invention, there is provided a data carrier signal carrying a computer program product as described herein. BRIEF DESCRIPTION OF THE DRAWINGS
[0115] Figure 1 The forward strand, reverse strand, forward complement strand, and reverse complement strand of the polynucleotide molecule are shown.
[0116] Figure 2 Examples of polynucleotide sequences (or insert sequences) having a 5' adaptor sequence and a 3' adaptor sequence are shown.
[0117] Figure 3 A typical polynucleotide having a 5' adaptor sequence and a 3' adaptor sequence is shown.
[0118] Figure 4 Typical solid supports are shown.
[0119] Figure 5 The stages of bridge amplification and generation of amplification clusters are shown, including (A) hybridization of a library chain with an immobilized primer; (B) generation of a template chain from the library chain; (C) dehybridization and washing of the library chain; (D) hybridization of the template chain with another immobilized primer; (E) generation of a template-complementary chain from the template chain by bridge amplification; (F) dehybridization of a sequence bridge; (G) hybridization of the template chain and the template-complementary chain with an immobilized primer; and (H) subsequent bridge amplification to provide multiple template chains and template-complementary chains.
[0120] Figure 6 Detection of nucleobases using 4-channel, 2-channel, and 1-channel chemistries is shown.
[0121] Figure 7 A method for selective sequencing is shown.
[0122] Figure 8 A method for selective amplification is shown, which includes (A) selectively cutting one type of fixed primer from a support; (B) only the template (or template complementary chain) chain complementary to the free fixed primer anneals and undergoes bridge amplification; (C) generating different ratios of template chain and template complementary chain; and (D) subsequent standard (non-selective) sequencing occurs in different ratios, thereby enabling signal differentiation.
[0123] Fig. 9 A method for selective amplification is shown, which includes (A) annealing a template chain and a template complementary chain to fixed primers; (B) adding a primer blocking agent that binds only to one type of fixed primer, thereby preventing extension from the one type of fixed primer and preventing extension from one type of fixed primer; (C) generating different ratios of template chains and template complementary chains; and (D) subsequent standard (non-selective) sequencing occurs in different ratios, thereby enabling signal differentiation.
[0124] Fig.10A method for selective amplification is shown, which includes (A) flowing one (or more) extension primer sequences containing at least one additional 5' nucleotide over the surface of a solid support; and (B) adding a primer blocking agent that binds only to one type of fixed primer and is complementary to the additional 5' nucleotide of the extension primer sequence, thereby preventing extension from the one type of fixed primer.
[0125] Fig.11 is a diagram showing graphical representations of sixteen distributions of signals generated by polynucleotide sequences according to one embodiment.
[0126] Fig.12 is a flow chart illustrating a method for base calling according to one embodiment.
[0127] Fig.13 Conceptually illustrates how to physically separate the forward strand polynucleotide sequence and the reverse strand polynucleotide sequence by swelling a deformable polymer. The left side of the figure illustrates the forward strand and the reverse strand hybridized together after clustering is complete. The right side of the figure illustrates that after swelling and denaturation, the tethered strands have been physically moved away from each other, thereby effectively preventing re-hybridization. This makes both strands available for priming and SBS sequencing.
[0128] Fig.14 Exemplary deformable polymers are shown; (A) shows the grafting of free "precursor" primers (P5 / P7) onto a polymer to form a deformable polymer comprising a first fixed primer and a second fixed primer in particle form; (B) shows the thermal responsiveness of the initial polymer without grafted primers (left) and the thermal responsiveness of the deformable polymer with primers grafted thereon (right). DETAILED DESCRIPTION
[0129] All patents, patent applications and other publications mentioned herein, including all sequences disclosed in these references, are expressly incorporated herein by reference to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference. The relevant portions of all references are incorporated herein by reference in their entirety for the purposes indicated by the context in which they are cited herein. However, the citation of any document shall not be construed as an admission of it as prior art to the present disclosure.
[0130] The present invention can be used for sequencing, in particular concurrent sequencing. Methods suitable for the present invention have been described in WO 08 / 041002, WO 07 / 052006, WO 98 / 44151, WO 00 / 18957, WO 02 / 06456, WO 07 / 107710, WO 05 / 068656, US13 / 661,524 and US 2012 / 0316086, the contents of which are incorporated herein by reference. More information can be found in US 20060024681, US 20060292611, WO 06 / 110855, WO 06 / 135342, WO 03 / 074734, WO 07 / 010252, WO 07 / 091077, WO 00 / 179553, WO 98 / 44152 and WO 2022 / 087150, the contents of which are incorporated herein by reference.
[0131] As used herein, the term "variant" refers to a variant polypeptide sequence or portion of a polypeptide sequence that retains the desired function of the complete non-variant sequence. For example, the desired function of a fixed primer is to retain the ability to bind (ie, hybridize) to a target sequence.
[0132] As used in any aspect described herein, a "variant" has at least 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, %, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% overall sequence identity. The sequence identity of the variants can be determined using any number of sequence alignment programs known in the art. For example, the Emboss Stretcher from EMBL-EBI can be used: https: / / www.ebi.ac.uk / Tools / psa / emboss_stretcher / (Default parameters were used: Pairwise output format, for proteins, matrix = BLOSUM62, Gap start = 1, Gap extension = 1; Pairwise output format, for nucleotides, matrix = DNAfull, Gap start = 16, Gap extension = 4).
[0133] As used herein, the term "fragment" refers to a series of functionally active contiguous nucleic acids from a longer nucleic acid sequence. The fragment can be at least 99%, at least 95%, at least 90%, at least 80%, at least 70%, at least 60%, at least 50%, at least 40% or at least 30% of the length of the longer nucleic acid sequence. In one embodiment, the fragment as used herein also retains the ability to bind to (i.e., hybridize to) the target sequence.
[0134] Sequencing generally includes four basic steps: 1) library preparation to form a plurality of target polynucleotides for identification; 2) cluster generation to form an array of amplified template polynucleotides; 3) sequencing the cluster arrays of these amplified template polynucleotides; and 4) data analysis to identify the characteristics of the target polynucleotides from the amplified template polynucleotide sequences. These steps are described in more detail below.
[0135] Library strand and template terminology
[0136] For a given double-stranded polynucleotide sequence 100 to be identified, the polynucleotide sequence 100 comprises a forward strand 101 of the sequence and a reverse strand 102 of the sequence. Figure 1 .
[0137] When the polynucleotide sequence 100 is replicated (e.g., using a DNA / RNA polymerase), a forward strand 101 of the sequence 100 and a complementary form of the reverse strand 102 of the sequence 100 are produced. Thus, replication of the polynucleotide sequence 100 provides a double-stranded polynucleotide sequence 100a and a double-stranded polynucleotide sequence 100b, wherein the double-stranded polynucleotide sequence 100a comprises the forward strand 101 of the sequence and the forward complementary strand 101′ of the sequence, and the double-stranded polynucleotide sequence 100b comprises the reverse strand 102 of the sequence and the reverse complementary strand 102′ of the sequence.
[0138] The term "template" can be used to describe a complementary form of a double-stranded polynucleotide sequence 100. Thus, a "template" comprises a forward complementary strand 101' of a sequence and a reverse complementary strand 102' of the sequence. Thus, by using the forward complementary strand 101' of a sequence as a template for complementary base pairing, a sequencing process (e.g., a sequencing-by-synthesis or a sequencing-by-ligation process) replicates the information present in the initial forward strand 101 of the sequence. Similarly, by using the reverse complementary strand 102' of a sequence as a template for complementary base pairing, a sequencing process (e.g., a sequencing-by-synthesis or a sequencing-by-ligation process) replicates the information present in the initial reverse strand 102 of the sequence.
[0139] The two strands in the template can also be referred to as the forward strand 101' of the template and the reverse strand 102' of the template. The complementary strand of the forward strand 101' of the template is referred to as the forward complementary strand 101 of the template, and the complementary strand of the reverse strand 102' of the template is referred to as the reverse complementary strand 102 of the template.
[0140] Generally, where the forward strand, reverse strand, forward complementary strand and reverse complementary strand are used herein without limiting whether they are about the initial polynucleotide sequence 100 or about the "template", these terms can be interpreted as referring to the "template".
[0141]
[0142] Library preparation
[0143] Library preparation is the first step in any high-throughput sequencing platform. These libraries allow templates to be produced by complementary base pairing, which can be clustered and amplified subsequently. During library preparation, nucleic acid sequences (such as genomic DNA samples, or cDNA or RNA samples) are converted into sequencing libraries, and then the nucleic acid sequences can be sequenced. Taking DNA samples as an example, the first step of library preparation is the random fragmentation of DNA samples. First, the sample DNA is fragmented, and a fragment of a specific size (usually 200bp to 500bp, but also larger) is connected, subcloned or "inserted" between two oligonucleotide adapters (adapter sequences). The initial sample DNA fragment is referred to as an "insertion sequence". Before being modified with an adapter sequence, the target polynucleotide can also be advantageously graded by size.
[0144] As described herein, the template to be generated generally comprises a single polynucleotide sequence, in particular a first polynucleotide sequence comprising a first portion and a second polynucleotide sequence comprising a second portion. These templates can be generated from a specific library according to methods known to those skilled in the art. However, some exemplary methods for preparing libraries suitable for generating such templates are described below.
[0145] In some embodiments, the library can be prepared by connecting the adapter sequence to a double-stranded polynucleotide sequence, each of which comprises a forward strand of the sequence and a reverse strand of the sequence, as described in more detail in, for example, WO 07 / 052006, which is incorporated herein by reference. In some cases, "labeling" can be used to attach sample DNA to adapters, as described in more detail in, for example, WO 10 / 048605, US2012 / 0301925, US2013 / 0143774, and WO 2016 / 189331, each of which is incorporated herein by reference. In labeling, double-stranded DNA is simultaneously fragmented and labeled with adapter sequences and PCR primer binding sites. The combined reaction eliminates the need for a separate mechanical shearing step during library preparation. These procedures can be used, for example, to prepare templates comprising a first polynucleotide sequence comprising a first portion and a second polynucleotide sequence comprising a second portion, wherein the first portion is the forward strand of the template and the second portion is the forward complement of the template, i.e., a copy of the forward strand (or alternatively, wherein the first portion is the reverse strand of the template and the second portion is the reverse complement of the template).
[0146] Where features are described herein with respect to the "forward" strand, it should be understood that these features are equally applicable to the "reverse strand".
[0147] When preparing a library by ligating an adapter sequence to a double-stranded polynucleotide sequence as described above, the library preparation may include ligating a first primer binding sequence 301′ (e.g., P5′, such as SEQ ID NO. 3) and a second terminal sequencing primer binding site 304 (e.g., SBS3′, such as SEQ ID NO. 8) to the 3′ end of the forward strand 101 of the sequence. Figure 2 The library preparation can be arranged so that the second terminal sequencing primer binding site 304 is attached (e.g., directly attached) to the 3′ end of the forward strand 101 of the sequence, and so that the first primer binding sequence 301′ is attached (e.g., directly attached) to the 3′ end of the second terminal sequencing primer binding site 304.
[0148] The library preparation may also include attaching the complementary sequence 303′ of the first terminal sequencing primer binding site (e.g., SBS12, such as SEQ ID NO.9) (also referred to herein as the first terminal sequencing primer binding site complementary sequence 303′) and the complementary sequence of the second primer binding sequence 302 (also referred to herein as the second primer binding complementary sequence 302) (e.g., P7, such as SEQ ID NO.2) to the 5′ end of the forward strand 101 of the sequence. The library preparation may be arranged such that the first terminal sequencing primer binding site complementary sequence 303′ is attached (e.g., directly attached) to the 5′ end of the forward strand 101 of the sequence, and the second primer binding complementary sequence 302 is attached (e.g., directly attached) to the 5′ end of the first terminal sequencing primer binding site complementary sequence 303′.
[0149] Thus, one strand of the polynucleotides in the polynucleotide library may comprise, in the 5′ to 3′ direction, a second primer binding complementary sequence 302 (e.g., P7), a first terminal sequencing primer binding site complementary sequence 303′ (e.g., SBS12), a forward strand 101 of the sequence, a second terminal sequencing primer binding site 304 (e.g., SBS3′), and a first primer binding sequence 301′ (e.g., P5′) ( Figure 2 ——Downlink).
[0150] Despite Figure 2 , but the chain may also include one or more index sequences. Therefore, a first index sequence (e.g., i7) may be set between the second primer binding complementary sequence 302 (e.g., P7) and the first terminal sequencing primer binding site complementary sequence 303′ (e.g., SBS12). Separately or in addition, a second index complementary sequence (e.g., i5′) may be set between the second terminal sequencing primer binding site 304 (e.g., SBS3′) and the first primer binding sequence 301′ (e.g., P5′). Therefore, in some embodiments, a chain of polynucleotides in the polynucleotide library may include a second primer binding complementary sequence 302 (e.g., P7), a first index sequence (e.g., i7), a first terminal sequencing primer binding site complementary sequence 303′ (e.g., SBS12), a forward strand 101 of the sequence, a second terminal sequencing primer binding site 304 (e.g., SBS3′), a second index complementary sequence (e.g., i5′), and a first primer binding sequence 301′ (e.g., P5′) in the 5′ to 3′ direction. Typical polynucleotides are Figure 3 As shown (lower link).
[0151] When a double-stranded sequence 100 is used, library preparation may further include attaching a second primer binding sequence 302′ (e.g., P7′) and a first terminal sequencing primer binding site 303 (e.g., SBS12′) to the 3′ end of the reverse strand 102 of the sequence. The library preparation may be arranged such that the first terminal sequencing primer binding site 303 is attached (e.g., directly attached) to the 3′ end of the reverse strand 102 of the sequence, and such that the second primer binding sequence 302′ is attached (e.g., directly attached) to the 3′ end of the first terminal sequencing primer binding site 303.
[0152] The library preparation may also include attaching a second terminal sequencing primer binding site complementary sequence 304′ (e.g., SBS3) (also referred to herein as the second terminal sequencing primer binding site complementary sequence 304′) and a first primer binding sequence complementary sequence 301 (also referred to herein as the first primer binding complementary sequence 301) (e.g., P5) to the 5′ end of the reverse strand 102 of the sequence. The library preparation may be arranged such that the second terminal sequencing primer binding site complementary sequence 304′ is attached (e.g., directly attached) to the 5′ end of the reverse strand 102 of the sequence, and such that the first primer binding complementary sequence 301 is attached (e.g., directly attached) to the 5′ end of the second terminal sequencing primer binding site complementary sequence 304′.
[0153] Thus, the other strand of the polynucleotides in the polynucleotide library may comprise, in the 5′ to 3′ direction, a first primer binding complementary sequence 301 (e.g., P5), a second terminal sequencing primer binding site complementary sequence 304′ (e.g., SBS3), a reverse strand of the sequence 102, a first terminal sequencing primer binding site 303 (e.g., SBS12′), and a second primer binding sequence 302′ (e.g., P7′) ( Figure 2 --winding).
[0154] Despite Figure 2Not shown, but the other chain may also include one or more index sequences. Therefore, a second index sequence (e.g., i5) may be set between the first primer binding complementary sequence 301 (e.g., P5) and the second terminal sequencing primer binding site complementary sequence 304′ (e.g., SBS3). Alternatively or in addition, a first index complementary sequence (e.g., i7′) may be set between the first terminal sequencing primer binding site 303 (e.g., SBS12′) and the second primer binding sequence 302′ (e.g., P7′). Therefore, in some embodiments, the other chain of the polynucleotides in the polynucleotide library may include the first primer binding complementary sequence 301 (e.g., P5), the second index sequence (e.g., i5), the second terminal sequencing primer binding site complementary sequence 304′ (e.g., SBS3), the reverse strand 102 of the sequence, the first terminal sequencing primer binding site 303 (e.g., SBS12′), the first index complementary sequence (e.g., i7′), and the second primer binding sequence 302′ (e.g., P7′) in the 5′ to 3′ direction. A typical polynucleotide such as Figure 3 As shown (on the chain).
[0155] As will be understood by the technician, double-stranded nucleic acid will generally be formed by two complementary polynucleotide chains, which are composed of deoxyribonucleotides or ribonucleotides connected by phosphodiester bonds, but may additionally contain one or more ribonucleotides and / or non-nucleotide chemical moieties and / or non-naturally occurring nucleotides and / or non-naturally occurring backbone bonds. Specifically, double-stranded nucleic acid may include non-nucleotide chemical moieties, such as joints or spacers at the 5' ends of one or two chains. As a non-limiting example, double-stranded nucleic acid may include methylated nucleotides, uracil bases, thiophosphate groups, peptide conjugates, etc. Such non-DNA or non-natural modifications may be included to give nucleic acid some desired properties, such as for realizing covalent attachment, non-covalent attachment or metal coordination attachment to a solid support, or serving as a spacer to position a cleavage site at an optimal distance from a solid support. Single-stranded nucleic acid is composed of one such polynucleotide chain. In the case where a polynucleotide chain is only partially hybridized with a complementary chain, for example, a long polynucleotide chain hybridized with a short nucleotide primer, it may still be referred to as a single-stranded nucleic acid herein.
[0156] A sequence comprising at least one primer binding sequence (a primer binding sequence and a sequencing primer binding site, in another aspect, a combination of a primer binding sequence, an index sequence, and a sequencing primer binding site) may be referred to herein as an adapter sequence, and the insert sequence is flanked by a 5' adapter sequence and a 3' adapter sequence. The primer binding sequence may also comprise a sequencing primer for index reading.
[0157] As used herein, "adapter" refers to a sequence comprising short sequence-specific oligonucleotides that are ligated to the 5' and 3' ends of each DNA (or RNA) fragment in a sequencing library as part of library preparation. The adaptor sequence may also comprise a non-peptide linker.
[0158] In another embodiment, the P5' primer binding sequence and the P7' primer binding sequence are complementary to a short primer sequence (or moss primer) present on the surface of the flow cell. The binding of P5' and P7' to their complementary sequences (P5 and P7) on, for example, the flow cell surface allows nucleic acid amplification. As used herein, "'" indicates a complementary strand.
[0159] The length of the primer binding sequence in the adapter that allows hybridization with an amplification primer (e.g., moss primer) is generally about 20 to 40 nucleotides, although the present invention is not limited to sequences of this length. The exact identity in the amplification primer (e.g., moss primer), and therefore the homologous sequence in the adapter is generally unimportant for the present invention, as long as the primer binding sequence can interact with the amplification primer to guide PCR amplification. The sequence of the amplification primer can be specific to the specific target nucleic acid of the desired amplification, but in other embodiments, these sequences can be "universal" primer sequences, which can amplify any target nucleic acid with known or unknown sequence, and these target nucleic acids have been modified to be able to amplify with universal primers. The design criteria of PCR primers are generally known to those of ordinary skill in the art.
[0160] Index sequence (also called barcode or tag sequence) is a unique short DNA (or RNA) sequence that is added to each DNA (or RNA) fragment during library preparation. Unique sequence allows many libraries to be merged together and sequenced simultaneously. Before final data analysis, sequencing reads from merged libraries are identified and classified based on their barcodes by calculation. Library multiplexing is also a useful technique when working with small genomes or targeting genomic regions of interest. Multiplexing with barcodes can exponentially increase the number of samples analyzed in a single run without significantly increasing running costs or running time. Examples of tag sequences are found in WO05 / 068656, the contents of which are incorporated herein by reference in their entirety. The tag can be read at the end of the first read, or also read at the end of the second read, for example using a sequencing primer complementary to the chain labeled P7. The present invention is not limited by the number of reads per cluster, for example two reads per cluster: three or more reads per cluster can be obtained simply by dehybridizing the first extended sequencing primer and rehybridizing the second primer before or after the cluster repopulation / chain resynthesis step. Methods for preparing suitable samples for indexing are described in, for example, WO 2008 / 093098, which is incorporated herein by reference. Single or dual indexes can also be used. Using a single index, up to 48 unique 6-base indexes can be used to generate a library of up to 48 unique markers. Using dual indexes, up to 24 unique 8-base index 1 sequences and up to 16 unique 8-base index 2 sequences can be used in combination to generate a library of up to 384 unique markers. Index pairs can also be used so that each i5 index and each i7 index are used only once. Using these unique dual indexes, it is possible to identify and filter index skipping, thereby providing even higher confidence in multiplexed samples.
[0161] The sequencing primer binding site is a sequencing and / or indexing primer binding site and indicates the starting point of the sequencing read. During the sequencing process, the sequencing primer anneals (i.e., hybridizes) to at least a portion of the sequencing primer binding site on the template strand. The polymerase binds to the site and incorporates complementary nucleotides base by base into the growing opposite strand.
[0162] Cluster generation and expansion
[0163] Once a double-stranded nucleic acid library is formed, typically the library has previously been subjected to denaturing conditions to provide single-stranded nucleic acids. Suitable denaturing conditions will be apparent to the skilled artisan, with reference to standard molecular biology protocols (Sambrook et al., 2001, Molecular Cloning, A Laboratory Manual, 4th edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor Laboratory Press, NY; Current Protocols, Ausubel et al., eds.). In one embodiment, chemical denaturation may be used.
[0164] After denaturation, the single-stranded library can be contacted in free solution to a solid support comprising surface capture moieties (eg, P5 Moss primer and P7 Moss primer).
[0165] Thus, embodiments of the present invention may be performed on a solid support 200, such as a flow cell. However, in alternative embodiments, seeding and clustering may be performed outside of a flow cell using other types of solid supports.
[0166] The solid support 200 may include a substrate 204. Figure 4 The substrate 204 includes at least one hole 203 (eg, a nanohole), and typically includes a plurality of holes 203 (eg, a plurality of nanoholes). For example, the substrate 204 can be a planar array of holes 203.
[0167] In one embodiment, the solid support comprises a plurality of first immobilized primers and a plurality of second immobilized primers.
[0168] Therefore, each well 203 may contain a plurality of first fixed primers 201. In addition, each well 203 may contain a plurality of second fixed primers 202. Therefore, each well 203 may contain a plurality of first fixed primers 201 and a plurality of second fixed primers 202.
[0169] When the deformable polymer is used in the form of particles (eg, nanoparticles), each particle can be considered as a single pore 203 .
[0170] The first immobilized primer 201 may be attached to the solid support 200 via the 5′ end of its polynucleotide chain. When extension occurs from the first immobilized primer 201 , the extension may be in a direction away from the solid support 200 .
[0171] The second immobilized primer 202 may be attached to the solid support 200 via the 5′ end of its polynucleotide chain. When extension occurs from the second immobilized primer 202 , the extension may be in a direction away from the solid support 200 .
[0172] The first fixed primer 201 may be different from the second fixed primer 202 and / or the complementary sequence of the second fixed primer 202. The second fixed primer 202 may be different from the first fixed primer 201 and / or the complementary sequence of the first fixed primer 201.
[0173] The first fixed primer 201 (or each of the first fixed primers) may include a sequence as defined by SEQ ID NO. 1 or 5 or a variant or fragment thereof. The second fixed primer 202 (or each of the second fixed primers) may include a sequence as defined by SEQ ID NO. 2 or a variant or fragment thereof. Although the first fixed primer 201 is shown here as corresponding to P5, and the second fixed primer 202 is shown here as corresponding to P7, the definitions of these primers may be exchanged, in other words, the first fixed primer 201 may instead correspond to P7, and the second fixed primer 202 may correspond to P5.
[0174] In some embodiments, the first fixed primer 201 and the second fixed primer 202 in the hole 203 may be separated from each other in space. In other words, the first fixed primer 201 may occupy the first region, and the second fixed primer 202 may occupy the second region, wherein the first region and the second region do not overlap each other. Suitable methods are described in WO 2020 / 005503, the contents of which are incorporated herein by reference. For example, the first fixed primer 201 may be grafted into the first polymer, and the second fixed primer 202 may be grafted onto the second polymer (for example, a second polymer having a main chain different from the first polymer); alternatively, the first fixed primer 201 may be grafted onto a region of a polymer (for example, a block copolymer), and the second fixed primer 202 may be grafted onto another region of the same polymer. This means that any signal generated (for example, the first signal and the second signal as mentioned herein) is spatially resolved.
[0175] In other embodiments, the first fixed primer 201 and the second fixed primer 202 in the hole 203 may not be separated from each other in space. In other words, the first fixed primer 201 may occupy a first region, and the second fixed primer 202 may occupy a second region, wherein the first region and the second region may correspond to the same region or may overlap substantially. This means that any signal generated (e.g., the first signal and the second signal as mentioned herein) cannot be resolved in space.
[0176] As a simple example, after the P5 primer and the P7 primer are attached to the solid support, the solid support can be contacted with the template to be amplified under the conditions of allowing hybridization (or annealing, such terms can be used interchangeably) between the template and the fixed primer. Usually, the template is added in the free solution under suitable hybridization conditions, which will be apparent to the technician. Usually, the hybridization conditions are, for example, 5 × SSC at 40 ° C. However, other temperatures can be used during hybridization, such as about 50 ° C to about 75 ° C, about 55 ° C to about 70 ° C or about 60 ° C to about 65 ° C. Then solid phase amplification can be carried out. The first step of amplification is a primer extension step, in which nucleotides are added to the 3 ' end of the fixed primer using a template to produce a complementary chain that is fully extended. Then the template is usually washed off from the solid support. The complementary chain includes a primer binding sequence (i.e., P5 'or P7 ') at its 3 ' end, which can be bridged to and combined with the second primer molecule fixed on the solid support. The amplification of other rounds (similar to standard PCR reactions) makes it possible to form a cluster or colony of the template molecule that is combined with the solid support. This is called clustering.
[0177] Therefore, solid phase amplification by a method similar to WO 98 / 44151 or WO 00 / 18957 (the contents of which are incorporated herein by reference in their entirety) will result in a cluster array consisting of colonies of "bridged" amplification products. This process is called bridge amplification. The two chains of the amplification product will be fixed to the solid support at or near the 5' end, and this attachment is derived from the initial attachment of the amplification primer. Typically, the amplification product in each colony will be derived from the amplification of a single template molecule. Other amplification procedures can be used and will be known to the technician. For example, amplification can be isothermally amplified using a strand displacement polymerase; or it can be exclusion amplification, as described in WO 2013 / 188582. More information about amplification can be found in WO 02 / 06456 and WO07 / 107710, the contents of which are incorporated herein by reference in their entirety.
[0178] By such methods, clusters of template molecules are formed, the clusters comprising copies of the template strand and copies of the complement of the template strand.
[0179] The steps for cluster generation and amplification of templates are described below and Figure 5 As described in, these templates include a first polynucleotide sequence comprising a first portion and a second polynucleotide sequence comprising a second portion.
[0180] In the case of using (separate) polynucleotide chains, each first polynucleotide sequence may be attached to the first fixed primer (via the 5' end of the first polynucleotide sequence), and each second polynucleotide sequence may be attached to the second fixed primer (via the 5' end of the second polynucleotide sequence). Each first polynucleotide sequence may include a second adapter sequence, wherein the second adapter sequence includes a portion that is substantially complementary to the second fixed primer (or is substantially complementary to the second fixed primer). The second adapter sequence may be located at the 3' end of the first polynucleotide sequence. Each second polynucleotide sequence may include a first adapter sequence, wherein the first adapter sequence includes a portion that is substantially complementary to the first fixed primer (or is substantially complementary to the first fixed primer). The first adapter sequence may be located at the 3' end of the second polynucleotide sequence.
[0181] In one embodiment, a solution comprising a polynucleotide library prepared by ligating adaptor sequences to a double-stranded polynucleotide sequence as described above can be passed through a flow cell.
[0182] A specific polynucleotide chain from a polynucleotide library to be sequenced comprises a second primer binding complementary sequence 302 (e.g., P7), a first terminal binding site complementary sequence 303′ (e.g., SBS12), a forward strand 101 of the sequence, a second terminal sequencing primer binding site 304 (e.g., SBS3′), and a first primer binding sequence 301′ (e.g., P5′) in the 5′ to 3′ direction, and can anneal with a first fixed primer 201 (e.g., P5 primer) located in a specific well 203 (via the first primer binding sequence 301′). Figure 5 A).
[0183] The polynucleotide library may contain other polynucleotide chains having different forward strands 101 of sequence. Such other polynucleotide chains may anneal to corresponding first immobilized primers 201 (e.g., P5 moss primers) in different wells 203, thereby enabling parallel processing of various different chains within the polynucleotide library.
[0184] A new polynucleotide chain can then be synthesized that extends from the first fixed primer 201 (e.g., P5 moss primer) in a direction away from the substrate 204. By using complementary base pairing, this produces a template chain that includes the first fixed primer 201 (e.g., P5 moss primer) attached to the solid support 200, the second terminal sequencing primer binding site complementary sequence 304' (e.g., SBS3), the forward strand 101' of the template (which represents a type of "first portion"), the first terminal sequencing primer binding site 303 (which represents a type of "first sequencing primer binding site") (e.g., SBS12'), and the second primer binding sequence 302' (e.g., P7') in the 5' to 3' direction. Figure 5B) This method may utilize an appropriate polymerase, such as DNA or RNA polymerase.
[0185] If the polynucleotides in the library contain an index sequence, a corresponding index sequence is also generated in the template.
[0186] The polynucleotide strands from the polynucleotide library can then be dehybridized and washed away, leaving the template strand ( Figure 5 C).
[0187] The second primer binding sequence 302′ (e.g., P7′) on the template strand can then anneal to the second immobilized primer 202 (e.g., P7 primer) located within the well 203. This forms a “bridge” ( Figure 5 D).
[0188] A new polynucleotide chain can then be synthesized by bridge amplification, which extends (initially) in a direction away from the substrate 204 from the second fixed primer 202 (e.g., P7 moss primer). By using complementary base pairing, this produces a template chain that includes the second fixed primer 202 (e.g., P7 moss primer) attached to the solid support 200, the first terminal sequencing primer binding site complementary sequence 303' (e.g., SBS12), the forward complementary strand 101 of the template (which represents a type of "second portion"), the second terminal sequencing primer binding site 304 (which represents a type of "second sequencing primer binding site") (e.g., SBS3'), and the first primer binding sequence 301' (e.g., P5') ( Figure 5 E) Again, this method may utilize a suitable polymerase, such as a DNA or RNA polymerase.
[0189] The strand attached to the second fixed primer 202 (eg, P7 moss primer) can then dehybridize with the strand attached to the first fixed primer 201 (eg, P5 moss primer) ( Figure 5 F).
[0190] Subsequent bridge amplification cycles may then result in amplification of the strand attached to the first fixed primer 201 (eg, P5 moss primer) and the strand attached to the second fixed primer 202 (eg, P7 moss primer). Figure 5D, the second primer binding sequence 302′ (e.g., P7′) attached to the template strand of the first fixed primer 201 (e.g., P5 moss primer) can then anneal with another second fixed primer 202 (e.g., P7 moss primer) located in the well 203. In a similar manner, the first primer binding sequence 301′ (e.g., P5′) attached to the template strand of the second fixed primer 202 (e.g., P7 moss primer) can then anneal with another first fixed primer 201 (e.g., P5 moss primer) located in the well 203 ( Figure 5 G).
[0191] Completion of bridge amplification and dehybridization can then provide an amplified (duoclonal) cluster, thereby providing a plurality of first polynucleotide sequences (i.e., "first portion") comprising the forward strand 101' of the template and a plurality of second polynucleotide sequences (i.e., "second portion") comprising the forward complementary strand 101 of the template ( Figure 5 H).
[0192] If desired, further bridge amplification cycles may be performed to increase the number of first polynucleotide sequences and second polynucleotide sequences within well 203 .
[0193] Other methods for achieving clustering and amplification include exclusion amplification (e.g., as described in WO 2013 / 188582), helicase-dependent amplification (e.g., as described in Vincent et al., EMBO Rep., 2004, Vol. 5, No. 8, pp. 795-800), and rolling circle amplification (e.g., as described in Mohsen et al., Acc. Chem. Res., 2016, Vol. 49, No. 11, pp. 2540-2550), the contents of which are incorporated herein by reference.
[0194] The above methods for clustering and amplification generally involve performing non-selective amplification. However, methods of the invention involving selective processing may include performing selective amplification, which will be described in further detail below under selective processing.
[0195] Sequencing
[0196] As described herein, the template provides information about the initial target polynucleotide sequence (e.g., identification of a genetic sequence, identification of an epigenetic modification). For example, a sequencing process (e.g., a sequencing-by-synthesis or sequencing-by-ligation process) can replicate the information present in the initial target polynucleotide sequence by using complementary base pairing.
[0197] In one embodiment, sequencing can be performed using any suitable "synthesis sequencing" technology, in which nucleotides are continuously added to free 3' hydroxyl groups in a cyclic manner, resulting in the synthesis of polynucleotide chains in the 5' to 3' direction. The properties of the added nucleotides can be determined after each addition. A specific sequencing method relies on the use of modified nucleotides that can act as reversible chain terminators. Such reversible chain terminators include removable 3' blocking groups. Once such modified nucleotides have been incorporated into the growing polynucleotide chain complementary to the template region to be sequenced, there is no free 3'-OH group available to guide further sequence extension, so the polymerase cannot add additional nucleotides. Once the properties of the bases incorporated into the growing chain have been determined, the 3' block can be removed to allow the addition of the next continuous nucleotide. By sorting the products derived from these modified nucleotides, the DNA sequence of the DNA template can be inferred. If each of the modified nucleotides has been attached with a different label known to correspond to a specific base, it is beneficial to distinguish the bases added at each incorporation step, then such reactions can be completed in a single experiment. Suitable labels are described in PCT application PCT / GB2007 / 001770, the contents of which are incorporated herein by reference in their entirety. Alternatively, separate reactions containing each modified nucleotide added separately may be performed.
[0198] The modified nucleotides may carry a label to facilitate their detection. Such a label may be configured to emit a signal, such as an electromagnetic signal or a (visible) light signal.
[0199] In a specific embodiment, the mark is a fluorescent label (e.g., a dye). Therefore, this mark can be configured to emit an electromagnetic signal or a (visible) light signal. A method for detecting fluorescently labeled nucleotides includes using a laser with a specific wavelength to the labeled nucleotides, or using other suitable illumination sources. The fluorescence from the mark on the incorporated nucleotide can be detected by a CCD camera or other suitable detection methods. Suitable detection methods are described in PCT / US2007 / 007991, the contents of which are incorporated herein by reference in their entirety.
[0200] However, the detectable label need not be a fluorescent label. Any label that allows detection of nucleotide incorporation into a DNA sequence can be used.
[0201] Each cycle may involve the simultaneous delivery of four different nucleotide types to the array of template molecules. Alternatively, different nucleotide types may be added sequentially, and an image of the array of template molecules may be obtained between each addition step.
[0202] In some embodiments, each nucleotide type may have a (spectrally) different label. In other words, four channels may be used to detect four nucleobases (also known as 4-channel chemistry) ( Figure 6 -left figure). For example, a first nucleotide type (e.g., A) may include a first label (e.g., configured to emit a first wavelength, such as red light), a second nucleotide type (e.g., G) may include a second label (e.g., configured to emit a second wavelength, such as blue light), a third nucleotide type (e.g., T) may include a third label (e.g., configured to emit a third wavelength, such as green light), and a fourth nucleotide type (e.g., C) may include a fourth label (e.g., configured to emit a fourth wavelength, such as yellow light). Four images may then be obtained, each using a detection channel that is selective for one of the four different labels. For example, a first nucleotide type (e.g., A) may be detected in a first channel (e.g., configured to detect a first wavelength, such as red light), a second nucleotide type (e.g., G) may be detected in a second channel (e.g., configured to detect a second wavelength, such as blue light), a third nucleotide type (e.g., T) may be detected in a third channel (e.g., configured to detect a third wavelength, such as green light), and a fourth nucleotide type (e.g., C) may be detected in a fourth channel (e.g., configured to detect a fourth wavelength, such as yellow light). Although specific pairings of bases and signal types (e.g., wavelengths) are described above, different signal types (e.g., wavelengths) and / or arrangements may also be used.
[0203] In some embodiments, less than four different labels may be used for detection of each nucleotide type.For example, synthesis sequencing may be performed using the methods and systems described in US2013 / 0079232, which is incorporated herein by reference.
[0204] Thus, in some embodiments, two channels can be used to detect four nucleobases (also referred to as 2-channel chemistry) ( Figure 6- middle figure). For example, a first nucleotide type (e.g., A) may include a first label (e.g., configured to emit a first wavelength, such as green light) and a second label (e.g., configured to emit a second wavelength, such as red light), a second nucleotide type (e.g., G) may not include the first label and may not include the second label, a third nucleotide type (e.g., T) may include the first label (e.g., configured to emit a first wavelength, such as green light) and may not include the second label, and a fourth nucleotide type (e.g., C) may not include the first label and may include the second label (e.g., configured to emit a second wavelength, such as red light). Then, using the detection channels for the first label and the second label, two images can be obtained. For example, a first nucleotide type (e.g., A) may be detected in both a first channel (e.g., configured to detect a first wavelength, such as red light) and a second channel (e.g., configured to detect a second wavelength, such as green light), a second nucleotide type (e.g., G) may not be detected in the first channel and may not be detected in the second channel, a third nucleotide type (e.g., T) may be detected in the first channel (e.g., configured to detect a first wavelength, such as red light) and may not be detected in the second channel, and a fourth nucleotide type (e.g., C) may not be detected in the first channel and may be detected in the second channel (e.g., configured to detect a second wavelength, such as green light). Although specific pairings of bases and signal types (e.g., wavelengths) and / or channel combinations are described above, different signal types (e.g., wavelengths) and / or arrangements may also be used.
[0205] In some embodiments, one channel can be used to detect four nucleobases (also referred to as 1 channel chemistry) ( Figure 6- right figure). For example, a first nucleotide type (e.g., A) may include a label that can be cut (e.g., configured to emit a wavelength such as green light), a second nucleotide type (e.g., G) may not include a label, a third nucleotide type (e.g., T) may include a label that cannot be cut (e.g., configured to emit a wavelength such as green light), and a fourth nucleotide type (e.g., C) may include a label receiving site that does not include a label. A first image may then be obtained, and subsequent processing may be performed to cut the label attached to the first nucleotide type and attach the label to the label receiving site on the fourth nucleotide type. A second image may then be obtained. For example, a first nucleotide type (e.g., A) may be detected in a channel in a first image (e.g., configured to detect a wavelength, such as green light) and not detected in a channel in a second image, a second nucleotide type (e.g., G) may not be detected in the channel in the first image and not detected in the channel in the second image, a third nucleotide type (e.g., T) may be detected in the channel in the first image (e.g., configured to detect a wavelength, such as green light) and detected in the channel in the second image (e.g., configured to detect a wavelength, such as green light), and a fourth nucleotide type (e.g., C) may not be detected in the channel in the first image and detected in the channel in the second image (e.g., configured to detect a wavelength, such as green light). Although specific pairings of bases and signal types (e.g., wavelengths) and / or image combinations are described above, different signal types (e.g., wavelengths), images, and / or arrangements may also be used.
[0206] In one embodiment, the sequencing process includes a first sequencing read and a second sequencing read. The first sequencing read and the second sequencing read can be performed concurrently. In other words, the first sequencing read and the second sequencing read can be performed simultaneously.
[0207] The first sequencing read may include the binding of a first sequencing primer (also referred to as a read 1 sequencing primer) to a first sequencing primer binding site (e.g., first terminal sequencing primer binding site 303 in templates that include a first polynucleotide sequence comprising the first portion and a second polynucleotide sequence comprising the second portion). The second sequencing read may include the binding of a second sequencing primer (also referred to as a read 2 sequencing primer) to a second sequencing primer binding site (e.g., second terminal sequencing primer binding site 304 in templates that include a first polynucleotide sequence comprising the first portion and a second polynucleotide sequence comprising the second portion).
[0208] This results in sequencing of the first part (e.g., the forward strand 101′ of the templates in the templates, which include a first polynucleotide sequence comprising the first part and a second polynucleotide sequence comprising the second part) and the second part (e.g., the forward complementary strand 101 of the templates in the templates, which include a first polynucleotide sequence comprising the first part and a second polynucleotide sequence comprising the second part).
[0209] Alternative sequencing methods include sequencing by ligation, for example as described in US 6,306,597 or WO 06 / 084132, the contents of which are incorporated herein by reference.
[0210] The above methods for sequencing generally involve performing non-selective sequencing. However, methods of the invention involving selective processing may include performing selective sequencing, which will be described in further detail below under selective processing.
[0211] Specifically, in the case of concurrent sequencing, the generated signals may be spatially resolved or not spatially resolved. In the case where the generated signals are spatially resolved, the signals generated by the first part and the second part can be resolved by interpreting these signals separately according to spatial separation, and non-selective processing methods (such as non-selective amplification and non-selective sequencing) can be used. However, in the case where the signals generated by the first part and the second part cannot be spatially resolved, other methods may be needed to resolve the generated information, and therefore, the signals that cannot be spatially resolved may involve selective processing methods (such as selective amplification and / or selective sequencing).
[0212] Selective treatment methods
[0213] In some embodiments, the selective processing method can be used to generate signals of different strengths. Thus, in some embodiments, the method can include selectively processing at least one first polynucleotide sequence comprising a first portion and at least one second polynucleotide sequence comprising a second portion, such that a certain proportion of the first portion is capable of generating a first signal and a certain proportion of the second portion is capable of generating a second signal, wherein the selective processing causes the strength of the first signal to be greater than the strength of the second signal.
[0214] The method may include selectively processing a plurality of first polynucleotide sequences, each comprising a first portion, and a plurality of second polynucleotide sequences, each comprising a second portion, such that a certain proportion of the first portions are capable of generating a first signal and a certain proportion of the second portions are capable of generating a second signal, wherein the selective processing causes the intensity of the first signal to be greater than the intensity of the second signal.
[0215] "Selective treatment" herein means an action to change the relative properties of the first part and the second part in at least one first polynucleotide sequence comprising the first part and at least one second polynucleotide sequence comprising the second part (or a plurality of first polynucleotide sequences each comprising the first part and a plurality of second polynucleotide sequences each comprising the second part) so that the intensity of the first signal is greater than the intensity of the second signal. The property can be, for example, the concentration of the first part capable of generating the first signal relative to the concentration of the second part capable of generating the second signal. The action can include, for example, performing selective amplification, performing selective sequencing, or preparing for selective sequencing.
[0216] In one embodiment, the selective treatment results in a concentration of a first moiety capable of generating a first signal being greater than a concentration of a second moiety capable of generating a second signal. In other words, the methods of the invention result in a change in the ratio of R1:R2 molecules, such as within a single cluster or a single well.
[0217] In one embodiment, the ratio may be between 1.25: 1 and 5: 1. In another embodiment, the ratio may be between 1.5: 1 and 3: 1. In yet further embodiments, the ratio may be about 2:1.
[0218] Selective processing can refer to performing selective sequencing. Alternatively, selective processing can refer to preparing for selective sequencing. Figure 7 As shown, in one example, a mixture of unblocked sequencing primers and blocked sequencing primers can be used to achieve selective sequencing.
[0219] Where the method of the invention involves (separate) polynucleotide chains, wherein a first polynucleotide chain has a first portion and a second polynucleotide chain has a second portion, the first polynucleotide chain may comprise a first sequencing primer binding site and the second polynucleotide chain may comprise a second sequencing primer binding site, wherein the first sequencing primer binding site and the second sequencing primer binding site have different sequences from each other and bind different sequencing primers.
[0220] In one embodiment, the binding of the first sequencing primer to the first sequencing primer site generates a first signal, and the binding of the second sequencing primer to the second sequencing primer site generates a second signal, wherein the intensity of the first signal is greater than the intensity of the second signal. This is applicable to embodiments in which the first polynucleotide chain comprises a first sequencing primer binding site and the second polynucleotide chain comprises a second sequencing primer binding site. This is achieved using a mixed population of a blocked second sequencing primer and an unblocked second sequencing primer that binds to the second sequencing primer site. Any ratio of blocked second primer: unblocked second primer can be used to generate a second signal with an intensity lower than the first signal, for example, the ratio of blocked primer: unblocked primer can be 20:80 to 80:20. In another embodiment, the ratio can be 1:2 to 2:1.
[0221] In still further embodiments, a 50:50 ratio of blocked second primer:unblocked second primer is used, which in turn generates a second signal having an intensity that is approximately 50% of the intensity of the first signal.
[0222] The first sequencing primer and the second sequencing primer may be added to the flow cell simultaneously, or separately but sequentially.
[0223] By "capped" is meant that the sequencing primer comprises a capping group at the 3' end of the sequencing primer. Suitable blocking groups include a hairpin loop (e.g., a polynucleotide attached to the 3' end, which comprises a site capable of cleavage in the 5' to 3' direction, such as a nucleotide comprising uracil, a loop portion, and a complementary portion, wherein the complementary portion is substantially complementary to all or part of the fixed primer), a deoxynucleotide, a deoxyribonucleotide, a hydrogen atom replacing a 3'-OH group, a phosphate group, a phosphorothioate group, a propyl spacer (e.g., -O-(CH2)3-OH replacing the 3'-OH group), a modification that blocks the 3'-hydroxyl group (e.g., a hydroxyl protecting group, such as a silyl ether group (e.g., trimethylsilyl, triethylsilyl, triisopropylsilyl, tert-butyl(dimethyl)silyl, tert-butyl(diphenyl)silyl), an ether group (e.g., benzyl, allyl, tert-butyl, methoxymethyl (MOM), 2-methoxyethoxymethyl (MEM), tetrahydropyranyl) or an acyl group (e.g., acetyl, benzoyl)) or an inverted nucleobase. However, the blocking group can be any modification that prevents extension (ie, elongation) of the primer by a polymerase.
[0224] The sequence of the sequencing primer and the sequence primer binding site are not critical to the methods of the present invention, as long as the sequencing primer is able to bind to the sequence primer binding site to achieve amplification and sequencing of the region to be identified.
[0225] In one aspect, the uncapped second sequencing primer and the capped second sequencing primer are present in the sequencing composition at equal concentrations. That is, the ratio of the capped second sequencing primer: the uncapped second sequencing primer is about 50:50. The sequencing composition may also include at least one additional (first) sequencing primer. In one example, the sequencing composition includes a capped second sequencing primer, an uncapped second sequencing primer, and at least one first sequencing primer.
[0226] like Figure 7 As shown, the amplified (binoclonal) clusters can be selectively sequenced (in this case, Figure 5 H after additional rounds of amplification), as described in further detail below. A plurality of first sequencing primers 501 are added. These sequencing primers 501 anneal to the first terminal sequencing primer binding site 303. A plurality of second unblocked sequencing primers 502a and a plurality of second blocked sequencing primers 502b are added simultaneously with the first sequencing primer 501, or are added sequentially (e.g., before or after the addition of the first sequencing primer 501). These second unblocked sequencing primers 502a and second blocked sequencing primers 502b anneal to the second terminal sequencing primer binding site 304. This then allows the forward strand 101′ (i.e., the “first portion”) of the template to be sequenced as well as the forward complementary strand 101 (i.e., the “second portion”) of the template to be sequenced, wherein a greater proportion of the forward strand 101′ (grey arrow) of the template is sequenced than a greater proportion of the forward complementary strand 101 (black arrow) of the template.
[0227] In other embodiments, the positions of the first sequencing primer and the second sequencing primer can be swapped. In other words, the first sequencing primer can be annealed to the second terminal sequencing primer binding site 304 instead, and the second sequencing primer can be annealed to the first terminal sequencing primer binding site 303 instead.
[0228] Alternatively or in addition, the selective treatment may refer to selective amplification, that is, selectively amplifying a portion (eg, the first portion or the second portion) of the first polynucleotide chain or the second polynucleotide chain.
[0229] In one example, the selective treatment includes selectively removing some or substantially all of the second fixed primers that have not been extended (extended to form a second polynucleotide chain), and performing at least one further amplification cycle to selectively amplify the first polynucleotide sequence relative to the second polynucleotide sequence. The fixed primer that has not been extended may be referred to herein as a free or unextended second fixed primer.
[0230] Thus, in this example, the selective removal of some or substantially all of the free second fixed primer is performed prior to at least one additional round of bridge amplification and prior to any sequencing of the target region. Thus, the ratio of the first polynucleotide capable of generating the first signal to the second polynucleotide capable of generating the second signal is altered, which in turn generates two signals of different intensities, thereby allowing concurrent sequencing of two sequences (or target regions within those sequences).
[0231] By "some or substantially all" is meant that at least 75%, at least 80%, at least 90%, or between 95% and 100% of the free second immobilized primer is removed.
[0232] The selective removal of all or substantially all of the free second fixed primer can be performed using a reagent capable of cleaving the fixed primer from the solid support. The reagent can be added after at least 5, at least 10, at least 15, or at least 20 to 24 rounds of bridge amplification. The reagent can be added alone or together with an amplification reagent to perform at least one additional round of amplification.
[0233] As mentioned above, and described in further detail in WO 2008 / 041002, the first fixed primer and the second fixed primer can be attached to the surface of the solid support by a joint. For the first fixed primer and the second fixed primer, the joint may be different. The joint can be any joint that can be cut; that is, the joint can include one or more parts, such as modified nucleotides, and the one or more parts enable selective cutting of the fixed primer from the surface of the solid support. As a non-limiting example, the joint can include uracil bases, thiophosphate groups, ribonucleotides, glycol bonds, disulfide bonds, peptides, etc., which can be included, not only allowing the joint to be covalently attached to the solid support, but also allowing the selective cutting of the joint.
[0234] In one example, the first fixed primer is attached to a solid support via a first connector, wherein the connector comprises uracil or 2-deoxyuridine. In this example, a free first fixed primer (i.e., an unextended primer) can be removed using uracil glycosylase. In one embodiment, a USER enzyme mixture (which is a mixture of uracil glycosylase and endonuclease VIII) can be used to remove the free first fixed primer.
[0235] In one example, the sequence of the first fixed primer comprises a variant of the following sequence or a fragment thereof:
[0236] 5'-PS-TTTTTTTTTTTAATGATACGGCGACCACCGAUCTACAC-3', wherein U = 2-deoxyuridine (SEQ ID NO. 11).
[0237] In another example, the second fixed primer is attached to the solid support via a second linker, wherein the linker comprises 8-oxoguanine. In this example, the free second fixed primer (ie, the unextended primer) can be removed using FPG glycosylase.
[0238] In one example, the sequence of the second fixed primer comprises a variant of the following sequence or a fragment thereof:
[0239] 5'-PS-TTTTTTTTTTCAAGCAGAAGACGGCATACGA[G 氧代 ]AT-3′, where [G 氧代 ] = 8-oxoguanine (SEQ ID NO. 12).
[0240] An example of this method is shown in Figure 8 In. The amplified (binoclonal) cluster can be selectively amplified, such as Figure 5 H. The solid support 200 comprises a free first fixed primer 201 and a free second fixed primer 202. The free second fixed primer 202 is cut from the solid support 200, thereby leaving the free first fixed primer 201 ( Figure 8 A).
[0241] The first primer binding sequence 301′ (e.g., P5′) on one set of template strands can then anneal with the free first fixed primer 201 (e.g., P5 primer) located in the well 203. In contrast, since the free second fixed primer 202 (e.g., P7 primer) has been removed, the second primer binding sequence 302′ (e.g., P7′) cannot anneal ( Figure 8 B).
[0242] After the bridge amplification cycle is performed, this results in the selective amplification of the template strand comprising the forward strand 101′ of the template and the first terminal sequencing primer binding site 303 relative to the template strand comprising the forward complementary strand 101 of the template and the second terminal sequencing primer binding site 304 ( Figure 8 C).
[0243] Standard (non-selective) sequencing is then performed to allow the forward strand 101′ of the template (i.e., the “first portion”) to be sequenced and the forward complement strand 101 of the template (i.e., the “second portion”) to be sequenced, wherein a greater proportion of the forward strand 101′ of the template (grey arrow) is sequenced compared to the proportion of the forward complement strand 101 of the template (black arrow). Figure 8 D).
[0244] In another example, selectively processing includes making the extension of some or substantially all of the second fixed primers that have not yet extended (extended to form the second polynucleotide chain) selectively end-capped. Likewise, these primers may be referred to as free or unextended second fixed primers in this article. The method may involve the use of primer end-capping agents, wherein the primer end-capping agents are configured to limit or prevent the synthesis of the chain (that is, polynucleotide chain) extended from the second fixed primer. The method may also involve carrying out at least one further amplification cycle. Because the free second fixed primer is blocked by the primer end-capping agent and cannot be extended, only the first fixed primer can be extended. This results in the amplification of only the first polynucleotide chain (that is, not the second polynucleotide chain), and therefore, the amount of the first polynucleotide sequence relative to the second polynucleotide sequence increases.
[0245] By "some or substantially all" is meant that at least 75%, at least 80%, at least 90%, or between 95% and 100% of the free second immobilized primer is capped.
[0246] After bridge amplification, the primer capping agent can be flowed through the solid support. In one embodiment, after at least 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 cycles, after at least 15, at least 20 or at least 25 rounds of bridge amplification, the primer capping agent is flowed through the solid support.
[0247] In one example, a primer capping agent is added while the first polynucleotide sequence is hybridized to the second fixed primer. That is, the primer capping agent is added during the amplification of at least the first polynucleotide chain and after extension. At this stage, the extended first polynucleotide chain bends (bridges) and hybridizes with the second fixed primer at its 5' end. Adding a primer capping agent at this stage prevents the extension of the second fixed primer, which would normally occur using the first polynucleotide chain as its template.
[0248] In one embodiment, the primer blocking agent is a blocked nucleotide. In one example, the blocked nucleotide can be A, C, T or G, but can be selected from A or G.
[0249] Likewise, "capped" means that the sequencing primer comprises a capping group at the 3' end of the sequencing primer. Suitable blocking groups include a hairpin loop (e.g., a polynucleotide attached to the 3′ end that contains a site capable of cleavage in the 5′ to 3′ direction, such as a nucleotide containing uracil, a loop portion, and a complementary portion, wherein the complementary portion is substantially complementary to all or part of the fixed primer), a deoxynucleotide, a deoxyribonucleotide, a hydrogen atom replacing a 3′-OH group, a phosphate group, a phosphorothioate group, a propyl spacer (e.g., —O—(CH2)3-OH replacing a 3′-OH group), a modification that blocks a 3′-hydroxy group (e.g., a hydroxyl protecting group, such as a silyl ether group (e.g., trimethylsilyl, triethylsilyl, triisopropylsilyl, tert-butyl(dimethyl)silyl, tert-butyl(diphenyl)silyl), an ether group (e.g., benzyl, allyl, tert-butyl, methoxymethyl (MOM), 2-methoxyethoxymethyl (MEM), tetrahydropyranyl) or an acyl group (e.g., acetyl, benzoyl)) or an inverted nucleobase. However, the blocking group may be any modification that prevents extension (ie, elongation) of the primer by a polymerase.The blocks may be reversible or irreversible.
[0250] The blocked nucleotides can be added as part of a mixture comprising blocked nucleotides and unblocked nucleotides. Alternatively, the blocked nucleotides can be added to the flow cell separately and before or after the unblocked nucleotides are added. After the blocked nucleotides are added, at least one more round of bridge amplification is performed.
[0251] An example of this method is shown in Fig. 9 In. The amplified (binoclonal) cluster can be selectively amplified, such as Figure 5 H. The first primer binding sequence 301′ (e.g., P5′) on one set of template strands can anneal with the first fixed primer 201 (e.g., P5 primer), and the second primer binding sequence 302′ (e.g., P7′) on the other set of template strands can anneal with the second fixed primer 202 (e.g., P7 primer) ( Fig. 9 A).
[0252] When the second primer binding sequence 302′ (e.g., P7′) anneals with the second fixed primer 202, the primer capping agent 601 is selectively installed on the 3′ end of the second fixed primer 202, while the 3′ end of the first fixed primer 201 is not installed ( Fig. 9 B).
[0253] Performing a bridge amplification cycle results in selective amplification of the template strand comprising the forward strand 101′ of the template and the first end sequencing primer binding site 303 relative to the template strand comprising the forward complementary strand 101 of the template and the second end sequencing primer binding site 304. The primer blocking agent 601 prevents extension from the second fixed primer 202. Fig. 9 C).
[0254] Standard (non-selective) sequencing is then performed to allow the forward strand 101′ of the template (i.e., the “first portion”) to be sequenced and the forward complement strand 101 of the template (i.e., the “second portion”) to be sequenced, wherein a greater proportion of the forward strand 101′ of the template (grey arrow) is sequenced compared to the proportion of the forward complement strand 101 of the template (black arrow). Fig. 9 D).
[0255] In an alternative example, the method includes flowing at least one or more extension primer sequences over the surface of a solid support (e.g., a flow cell), wherein such sequences can bind (e.g., hybridize) to a free, immobilized primer (e.g., P5 or P7), and wherein these extension primer sequences also contain at least one additional 5′ nucleotide; and (b) adding a primer capping agent, wherein the primer capping agent is complementary to the additional 5′ nucleotide.
[0256] The extension primer sequence can be substantially complementary to the first fixed primer or the second fixed primer (eg, P5 or P7), or substantially complementary to a portion of the first fixed primer or the second fixed primer.
[0257] The additional 5' nucleotide may be selected from A, T, C or G, but may be selected from T (or U) or C. In one embodiment, the additional 5' nucleotide is not the complementary sequence of the 3' nucleotide of the second fixed primer (wherein the extension primer sequence binds to the first fixed primer), or is not the complementary sequence of the 3' nucleotide of the first fixed primer (wherein the extension primer sequence binds to the second fixed primer). For example, where the first fixed primer is P5 (e.g., as defined in SEQ ID NO: 1 or 5) and the second fixed primer is P7 (e.g., as defined in SEQ ID NO: 2), and where the extension primer sequence binds to the first fixed primer, the additional 5' nucleotide is not A. Similarly, where the extension primer sequence binds to the second fixed primer, the additional 5' nucleotide is not G.
[0258] In one embodiment, the primer blocking agent is a blocked nucleotide, for example, as described above. In one embodiment, the blocked nucleotide may be A, C, T or G, but may be selected from A or G. Thus, where the additional 5' nucleotide is T or U, the primer blocking agent is A, and where the additional 5' nucleotide is C, the primer blocking agent is G.
[0259] Likewise, the extension primer sequence and primer capping agent can be passed over the solid support after bridge amplification. In one embodiment, the primer capping agent can be passed over the solid support after at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, at least 20, or at least 25 rounds of bridge amplification.
[0260] In one embodiment, the extension primer sequence is selected from SEQ ID NO. 13 to 24 or variants or fragments thereof.
[0261] An example of this method is shown in Fig.10 In. The amplified (binoclonal) cluster can be selectively amplified, such as Figure 5 H; thus, after multiple rounds of amplification, a cluster is formed, which contains both the extended first (e.g., P5) fixed polynucleotide chain and the second (e.g., P7) fixed polynucleotide chain. Before the next round of amplification, one (or more) extension primer sequences are flowed over the surface of the solid support 200. The extension primer sequence 701 is substantially complementary to at least a portion (if not all) of the fixed primer (e.g., P5 or P7) and binds to the fixed primer (e.g., P5 or P7), such as Fig.10 As shown in A. Fig.10 As shown in A, the extension primer sequence 701 includes at least one additional 5' nucleotide.
[0262] After adding the extension primer sequence 701, the primer capping agent 601 is added and allowed to flow over the surface of the solid support (e.g., a flow cell). Since the primer capping agent 601 is complementary to the additional 5' nucleotide of the extension primer sequence 701, the primer capping agent 601 binds to the 3' end of the fixed strand hybridized with the extension primer sequence 701, such as Fig.10 B. Therefore, the addition of primer blocking agent 601 not only prevents the extension of the fixed strand (e.g., P5 or P7), but also makes the fixed primer (P5 or P7) unavailable for hybridization with other extended strands (e.g., 101′) and subsequent bridge amplification (see Fig.10 B).
[0263] At least one more cycle of bridge amplification results in selective amplification of the template strand containing the forward strand 101′ of the template (at a ratio of 101′ to 101 of 2:1). Fig. 9D, Performing standard (non-selective) sequencing allows sequencing of the forward strand 101′ of the template (i.e., the “first portion”) and sequencing of the forward complement strand 101 of the template (i.e., the “second portion”), wherein a greater proportion of the forward strand 101′ of the template (grey arrow) is sequenced compared to the proportion of the forward complement strand 101 of the template (black arrow) Fig. 9 D).
[0264] The extension primer sequence can be added as part of the above-mentioned amplification mixture. Alternatively, the capped fixed primer binding sequence can be added to the flow cell separately and can be added before adding the amplification mixture. After adding the capped fixed primer binding sequence, at least one round of bridge amplification is performed.
[0265] Data Analysis Using 16QAM
[0266] Fig.11 is a scatter plot showing examples of sixteen distributions of signals generated by the polynucleotide sequences disclosed herein.
[0267] Fig.11 The scatter plot shows sixteen distributions (or partitions) of intensity values from a combination of a brighter signal (i.e., a first signal as described herein) and a darker signal (i.e., a second signal as described herein); as described above, these two signals may be co-located and cannot be optically resolved. Fig.11 The intensity values shown in may be up to a scaling factor or a normalization factor; the units of the intensity values may be arbitrary or relative (i.e., representing a ratio of an actual intensity to a reference intensity). The sum of the brighter signal generated by the first portion and the dimmer signal generated by the second portion produces a combined signal. The combined signal may be captured by the first optical channel and the second optical channel. Since the brighter signal may be A, T, C, or G, and the dimmer signal may be A, T, C, or G, there are sixteen possibilities for the combined signal, corresponding to sixteen distinguishable patterns when optically captured. That is, each of the sixteen possibilities corresponds to Fig.11 The computer system can map the generated combined signal to one of the sixteen partitions to determine the nucleobase added at the first portion and the nucleobase added at the second portion, respectively.
[0268] For example, when the combined signal is mapped to partition 1612 for base calling cycles, the computer processor base calls both the nucleobase added at the first portion and the nucleobase added at the second portion as C. When the combined signal is mapped to partition 1614 for base calling cycles, the processor base calls the nucleobase added at the first portion as C, and the nucleobase added at the second portion as T. When the combined signal is mapped to partition 1616 for base calling cycles, the processor base calls the nucleobase added at the first portion as C, and the nucleobase added at the second portion as G. When the combined signal is mapped to partition 1618 for base calling cycles, the processor base calls the nucleobase added at the first portion as C, and the nucleobase added at the second portion as A.
[0269] When the combined signal is mapped to partition 1622 for base calling cycles, the processor base calls the nucleobase added at the first portion as T, and the nucleobase added at the second portion as C. When the combined signal is mapped to partition 1624 for base calling cycles, the processor base calls both the nucleobase added at the first portion and the nucleobase added at the second portion as T. When the combined signal is mapped to partition 1626 for base calling cycles, the processor base calls the nucleobase added at the first portion as T, and the nucleobase added at the second portion as G. When the combined signal is mapped to partition 1628 for base calling cycles, the processor base calls the nucleobase added at the first portion as T, and the nucleobase added at the second portion as A.
[0270] When the combined signal is mapped to partition 1632 for base calling cycles, the processor base calls the nucleobase added at the first portion as G, and the nucleobase added at the second portion as C. When the combined signal is mapped to partition 1634 for base calling cycles, the processor base calls the nucleobase added at the first portion as G, and the nucleobase added at the second portion as T. When the combined signal is mapped to partition 1636 for base calling cycles, the processor base calls both the nucleobase added at the first portion and the nucleobase added at the second portion as G. When the combined signal is mapped to partition 1638 for base calling cycles, the processor base calls the nucleobase added at the first portion as G, and the nucleobase added at the second portion as A.
[0271] When the combined signal is mapped to partition 1642 for base calling cycles, the processor base calls the nucleobase added at the first portion as A and the nucleobase added at the second portion as C. When the combined signal is mapped to partition 1644 for base calling cycles, the processor base calls the nucleobase added at the first portion as A and the nucleobase added at the second portion as T. When the combined signal is mapped to partition 1646 for base calling cycles, the processor base calls the nucleobase added at the first portion as A and the nucleobase added at the second portion as G. When the combined signal is mapped to partition 1648 for base calling cycles, the processor base calls both the nucleobase added at the first portion and the nucleobase added at the second portion as A.
[0272] In this particular example, T is configured to emit signals in both the Image 1 channel and the Image 2 channel, A is configured to emit signals only in the Image 1 channel, C is configured to emit signals only in the Image 2 channel, and G does not emit signals in either channel. However, the same effect can be achieved by performing dye swaps using different arrangements of nucleobases. For example, A can be configured to emit signals in both the Image 1 channel and the Image 2 channel, T can be configured to emit signals only in the Image 1 channel, C can be configured to emit signals only in the Image 2 channel, and G can be configured to emit signals in neither channel.
[0273] Further details regarding performing base calls based on a scatter plot with sixteen partitions can be found in U.S. Patent Application Publication No. 2019 / 0212294, the disclosure of which is incorporated herein by reference.
[0274] Fig.12 1700 is a flow chart showing a method 1700 of base calling according to the present disclosure. The method allows two (or more) parts (e.g., a first part and a second part) to be sequenced simultaneously in a single sequencing run according to a single combined signal obtained from the first part and the second part, thereby requiring less sequencing reagent consumption and generating data faster from both the first part and the second part. Further, compared to existing next-generation sequencing methods, the simplified method can reduce the number of workflow steps while producing the same yield. Therefore, the simplified method can shorten the sequencing run time.
[0275] like Fig.12 As shown, the disclosed method 1700 may start at block 1701. The method may then proceed to block 1710.
[0276] At block 1710, intensity data is obtained. The intensity data includes first intensity data and second intensity data. The first intensity data includes a combined intensity of a first signal component obtained based on a first nucleobase corresponding to the first portion and a second signal component obtained based on a second nucleobase corresponding to the second portion. Similarly, the second intensity data includes a combined intensity of a third signal component obtained based on a first nucleobase corresponding to the first portion and a fourth signal component obtained based on a second nucleobase corresponding to the second portion.
[0277] Thus, the first part is capable of generating a first signal comprising a first signal component and a third signal component.The second part is capable of generating a second signal comprising a second signal component and a fourth signal component.
[0278] As described above, the first part and the second part may be arranged on a solid support so that signals from the first part and the second part are detected by a single sensing portion and / or may include a single cluster so that the first signal and the second signal from each of the corresponding first part and the second part cannot be spatially distinguished.
[0279] In one example, obtaining intensity data includes selecting intensity data corresponding to two (or more) different parts (e.g., a first part and a second part). In one example, the intensity data is selected based on a purity score. The purity score can be calculated as the ratio of the brightest base signal intensity divided by the sum of the brightest base signal intensity and the second brightest base signal intensity. The desired purity score may vary, depending on the expected intensity ratio of the light emissions associated with the different parts. As described above, it may be desirable to produce clusters including a first part and a second part that produce signals in a ratio of 2:1. In one example, the purity score corresponding to high-quality data of two parts with an intensity ratio of 2:1 may be approximately 0.8 to 0.9.
[0280] After the intensity data has been obtained, the method may proceed to block 1720. In this step, one of a plurality of classifications is selected based on the intensity data. Each classification represents a possible combination of a corresponding first nucleobase and a second nucleobase. In one example, the plurality of classifications include: Fig.11 Sixteen classifications shown, these sixteen classifications represent the unique combination of the first core base and the second core base separately. In the case of two parts, there are sixteen possible combinations of the first core base and the second core base. Based on the first intensity data and the second intensity data, select this classification to include the combined intensity based on the first signal component and the second signal component and the combined intensity of the third signal component and the fourth signal component to select this classification.
[0281] Then the method can proceed to frame 1730, wherein base calling is performed to the corresponding first core base and the second core base based on the classification selected in frame 1720. The signal generated during the sequencing cycle indicates the identity of the core base added during sequencing (e.g., using synthetic sequencing). It should be understood that there is a direct correspondence between the identity of the core base incorporated and the identity of the complementary base at the corresponding position of the template sequence bound on the solid support. Therefore, any reference to the base calling of the corresponding core base at the two parts herein covers the base calling of the core base hybridized with the template sequence, and alternatively or additionally, the identification of the corresponding core base of the template sequence. The method can then end at frame 1740.
[0282] Deformable polymers
[0283] According to one embodiment of the present invention, a deformable polymer is described, the deformable polymer comprising:
[0284] a first plurality of immobilized primers; and
[0285] a plurality of second fixed primers,
[0286] wherein the plurality of first fixed primers and the plurality of second fixed primers occupy a first set of positions on the deformable polymer,
[0287] Wherein the deformable polymer is configured such that when the deformable polymer is exposed to a deformation trigger, the plurality of first fixed primers and the second fixed primers are shifted to a second set of positions on the deformable polymer that is different from the first set of positions.
[0288] In one embodiment, the second immobilized primer is different in sequence from the first immobilized primer.
[0289] According to one embodiment, the composition of matter comprises:
[0290] polymers capable of deformation;
[0291] a first plurality of immobilized primers; and
[0292] a plurality of second fixed primers,
[0293] wherein the plurality of first fixed primers and the plurality of second fixed primers occupy a first set of positions on the deformable polymer,
[0294] Wherein the deformable polymer is configured such that when the composition is exposed to a deformation trigger, the plurality of first immobilized primers and the second immobilized primers are translocated to a second set of locations on the deformable polymer that is different from the first set of locations.
[0295] In some embodiments, the composition may include a plurality of fixed primers. In some embodiments, the plurality of primers may be attached to a polymer capable of deformation. In some embodiments, the composition may include a polymer capable of deformation, which is functionally attached to a plurality of fixed primers. In some embodiments, fixation may be fixed on a polymer capable of deformation. In some embodiments, the composition may be contacted with a solution containing a free solution polymer. In some embodiments, the composition may be in chemical equilibrium with the free primer in the solution, and the solution may be contacted with the fixed primer. In some embodiments, the fixed primer may be covalently bonded to a polymer capable of deformation in the composition.
[0296] When the template strand and the template complementary strand are generated, these strands have a tendency to form self-hybridization structures (e.g., when bridge amplification is performed, the template strand and the template complementary strand form a double-stranded bridge structure). In a typical sequencing process, one set of strands (e.g., all template strands or all template complementary strands) is cut and washed away, leaving single-stranded portions available for sequencing. However, in the sequencing method according to the present invention (e.g., when it is desired to sequence both the template strand and the template complementary strand, i.e., to sequence the forward strand of the template and the forward complementary strand of the template, or the forward strand of the template and the reverse strand of the template concurrently), self-hybridization may interfere with the sequencing process due to the lack of single-stranded portions.
[0297] Advantageously, the ability of the deformable polymer to displace the first fixed primer and the second fixed primer located at the first set of positions to a second set of positions different from the first set of positions allows the template strand and the template complementary strand (once extended from the first fixed primer and the second fixed primer) to separate from each other. This effectively causes the template strand and the template complementary strand to become single stranded once exposed to the deformation trigger, and thus available for priming and sequencing. Therefore, the forward strand and the forward complementary strand of the template (or the forward strand and the reverse strand of the template) are sequenced without the problem of self-hybridization.
[0298] The first set of positions may correspond to the spatial positions of the 5′ end of the first fixed primer and the 5′ end of the second fixed primer on the deformable polymer (e.g., the attachment points of the first fixed primer and the second fixed primer to the deformable polymer); similarly, the second set of positions may correspond to the spatial positions of the 5′ end of the first fixed primer and the 5′ end of the second fixed primer on the deformable polymer (e.g., the attachment points of the first fixed primer and the second fixed primer to the deformable polymer), wherein these spatial positions are different from the first set of positions. Alternatively, the first set of positions may correspond to the spatial positions of the 3′ end of the first fixed primer and the 3′ end of the second fixed primer on the deformable polymer; similarly, the second set of positions may correspond to the spatial positions of the 3′ end of the first fixed primer and the 3′ end of the second fixed primer on the deformable polymer, wherein these spatial positions are different from the first set of positions. Alternatively, the first set of positions may correspond to the spatial positions of the central portion of the first fixed primer and the central portion of the second fixed primer on the deformable polymer; similarly, the second set of positions may correspond to the spatial positions of the central portion of the first fixed primer and the central portion of the second fixed primer on the deformable polymer, wherein these spatial positions are different from the first set of positions.
[0299] The type of displacement is not particularly limited, provided that the second set of positions is different from the first set of positions. For example, the displacement may involve expansion of the deformable polymer or contraction of the deformable polymer; and / or reorganization of the first fixed primer and the second fixed primer.
[0300] In one embodiment, the deformation trigger may cause a volume expansion of the deformable polymer. In other words, the deformable polymer may be expandable. The volume expansion may be an increase in volume of at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 110%, 120%, 130%, 140%, or 150%.
[0301] In another embodiment, the expansion can be at least a 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 110%, 120%, 130%, 140%, or 150% increase in volume. In still further embodiments, the expansion can be at least a 50%, 60%, 70%, 80%, 90%, 100%, 110%, 120%, 130%, 140%, or 150% increase in volume. In still further embodiments, the expansion can be at least a 100%, 110%, 120%, 130%, 140%, or 150% increase in volume. Generally speaking, the greater the expansion, the less likely the template strand and the template-complement strand will remain hybridized to each other.
[0302] In some embodiments, the upper limit of the volume expansion of the deformable polymer may be as high as 2000%, 1500%, 1000%, 950%, 900%, 850%, 800%, 750%, 700%, 650%, 600%, 550%, 500%, 450%, 400%, 350% or 300% volume increase.
[0303] In another embodiment, the expansion may be at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 110%, 120%, 130%, 140%, or 150% volume increase, up to 2000% volume increase. In a further embodiment, the expansion may be at least 50%, 60%, 70%, 80%, 90%, 100%, 110%, 120%, 130%, 140%, or 150% volume increase, up to 800% volume increase. In yet a further embodiment, the expansion may be at least 100%, 110%, 120%, 130%, 140%, or 150% volume increase, up to 400% volume increase.
[0304] In one embodiment, the deformation trigger may cause a volume contraction of the deformable polymer. In other words, the deformable polymer may be shrinkable. The volume contraction may be a volume reduction of at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 110%, 120%, 130%, 140%, or 150%.
[0305] In another embodiment, the contraction may be a volume reduction of at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 110%, 120%, 130%, 140%, or 150%. In a further embodiment, the contraction may be a volume reduction of at least 50%, 60%, 70%, 80%, 90%, 100%, 110%, 120%, 130%, 140%, or 150%. In yet a further embodiment, the contraction may be a volume reduction of at least 100%, 110%, 120%, 130%, 140%, or 150%. Generally speaking, the greater the contraction, the less likely the template strand and the template-complement strand will remain hybridized to each other.
[0306] In some embodiments, the upper limit of the volume shrinkage of the deformable polymer may be as high as 2000%, 1500%, 1000%, 950%, 900%, 850%, 800%, 750%, 700%, 650%, 600%, 550%, 500%, 450%, 400%, 350% or 300% volume reduction.
[0307] In another embodiment, the shrinkage can be at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 110%, 120%, 130%, 140% or 150% volume reduction, up to 2000% volume reduction. In a further embodiment, the shrinkage can be at least 50%, 60%, 70%, 80%, 90%, 100%, 110%, 120%, 130%, 140% or 150% volume reduction, up to 800% volume reduction. In yet another further embodiment, the shrinkage can be at least 100%, 110%, 120%, 130%, 140% or 150% volume reduction, up to 400% volume reduction.
[0308] In one embodiment, this deformation triggering can cause the reorganization of the first fixed primer and the second fixed primer. In other words, reorganization can refer to the situation that the first fixed primer and the second fixed primer experience spatial rearrangement (for example, random spatial rearrangement). This can occur in the embodiment that can deformable polymer can expand, in the embodiment that can deformable polymer can shrink, or in the embodiment that has the first fixed primer and the second fixed primer at the second group of positions and has the first fixed primer and the second fixed primer at the first group of positions.
[0309] In one embodiment, where the deformable polymer having the first fixed primer and the second fixed primer at the second set of positions has a similar volume to the deformable polymer having the first fixed primer and the second fixed primer at the first set of positions, the shuffling may be accompanied by a 20% volume reduction to a 20% volume increase of the deformable polymer. In another embodiment, the shuffling may be accompanied by a 10% volume reduction to a 10% volume increase of the deformable polymer. In a further embodiment, the shuffling may be accompanied by a 5% volume reduction to a 5% volume increase of the deformable polymer.
[0310] The reorganization may be triggered by expanding the deformable polymer and then contracting the deformable polymer, or contracting the deformable polymer and then expanding the deformable polymer. In such cases, after the expansion and contraction or contraction and expansion, the first fixed primer and the second fixed primer may then be located at different positions than before the expansion and contraction or contraction and expansion.
[0311] The type of deformation trigger is not particularly limited and may for example comprise either a physical trigger and / or a (bio)chemical trigger.
[0312] In one embodiment, the physical trigger may include a temperature change of a deformable polymer. For example, the physical trigger may involve heating or cooling a deformable polymer. Suitable thermoresponsive polymers are known to those skilled in the art, and once primers have been fixed to a deformable polymer (i.e., forming a plurality of first fixed primers and second fixed primers), these thermoresponsive polymers may be used as deformable polymers.
[0313] In some embodiments, the deformable polymer may have an upper critical solution temperature and / or a lower critical solution temperature.
[0314] For example, the physical trigger may involve heating the deformable polymer from below the upper critical solution temperature to above the upper critical solution temperature. In other embodiments, the physical trigger may involve heating the deformable polymer from below the lower critical solution temperature to above the lower critical solution temperature.
[0315] In other embodiments, the physical trigger may involve cooling the deformable polymer from above the upper critical solution temperature to below the upper critical solution temperature. In other embodiments, the physical trigger may involve cooling the deformable polymer from above the lower critical solution temperature to below the lower critical solution temperature.
[0316] In one embodiment, the physical trigger may involve cooling the deformable polymer from a temperature between 50°C and 100°C (in another embodiment, between 55°C and 95°C; in a further embodiment, between 60°C and 90°C) to a temperature between 10°C and 40°C (in another embodiment, between 15°C and 35°C; in a further embodiment, between 20°C and 30°C). In another embodiment, the physical trigger may involve heating the deformable polymer from a temperature between 10°C and 40°C (in another embodiment, between 15°C and 35°C; in a further embodiment, between 20°C and 30°C) to a temperature between 50°C and 100°C (in another embodiment, between 55°C and 95°C; in a further embodiment, between 60°C and 90°C).
[0317] In one embodiment, the (bio)chemical trigger may include a change in salt concentration. Suitable polymers that are responsive to salt concentration are known to those skilled in the art, and once the primers have been fixed to a polymer that can be deformed (i.e., forming a plurality of first fixed primers and second fixed primers), these polymers can be used as a polymer that can be deformed.
[0318] For example, a (bio)chemical trigger may involve exposure to a solution of a salt having a concentration greater than 10 mM, greater than 20 mM, greater than 50 mM, greater than 100 mM, greater than 150 mM, greater than 200 mM, greater than 250 mM, greater than 300 mM, greater than 350 mM, greater than 400 mM, greater than 450 mM, or greater than 500 mM. In some embodiments, the salt may be sodium chloride. Thus, a (bio)chemical trigger may involve exposure to a solution comprising sodium chloride having a concentration greater than 10 mM, greater than 20 mM, greater than 50 mM, greater than 100 mM, greater than 150 mM, greater than 200 mM, greater than 250 mM, greater than 300 mM, greater than 350 mM, greater than 400 mM, greater than 450 mM, or greater than 500 mM.
[0319] In some embodiments, the upper limit of salt concentration can be up to 1000 mM, 900 mM, 800 mM, 700 mM, or 600 mM. The upper limit of sodium chloride concentration can be up to 1000 mM, 900 mM, 800 mM, 700 mM, or 600 mM.
[0320] In another embodiment, the salt concentration may be greater than 10mM, greater than 20mM, greater than 50mM, greater than 100mM, greater than 150mM, greater than 200mM, greater than 250mM, greater than 300mM, greater than 350mM, greater than 400mM, greater than 450mM, or greater than 500mM, up to 1000mM. In a further embodiment, the salt concentration may be greater than 100mM, greater than 150mM, greater than 200mM, greater than 250mM, greater than 300mM, greater than 350mM, greater than 400mM, greater than 450mM, or greater than 500mM, up to 800mM. In yet a further embodiment, the salt concentration may be greater than 250mM, greater than 300mM, greater than 350mM, greater than 400mM, greater than 450mM, or greater than 500mM, up to 600mM.
[0321] In another embodiment, the sodium chloride concentration may be greater than 10mM, greater than 20mM, greater than 50mM, greater than 100mM, greater than 150mM, greater than 200mM, greater than 250mM, greater than 300mM, greater than 350mM, greater than 400mM, greater than 450mM, or greater than 500mM, up to 1000mM. In a further embodiment, the sodium chloride concentration may be greater than 100mM, greater than 150mM, greater than 200mM, greater than 250mM, greater than 300mM, greater than 350mM, greater than 400mM, greater than 450mM, or greater than 500mM, up to 800mM. In yet a further embodiment, the sodium chloride concentration may be greater than 250mM, greater than 300mM, greater than 350mM, greater than 400mM, greater than 450mM, or greater than 500mM, up to 600mM.
[0322] In one embodiment, the (bio)chemical trigger may comprise a pH change. Suitable polymers that are responsive to pH are known to those skilled in the art and can be used as deformable polymers once the primers have been fixed to the deformable polymer (i.e., forming a plurality of first fixed primers and second fixed primers).
[0323] In some embodiments, the deformable polymer may include a polyelectrolyte; or may be a copolymer including a polyelectrolyte. In other embodiments, the polyelectrolyte may be an anionic polyelectrolyte, a cationic polyelectrolyte, or an amphiphilic polyelectrolyte.
[0324] For example, the (bio)chemical trigger may involve exposure to an acidic pH. In one embodiment, the (bio)chemical trigger may involve exposure to a pH less than 7, less than 6.5, less than 6, less than 5.5, less than 5, less than 4.5, less than 4, less than 3.5, or less than 3. In another embodiment, the (bio)chemical trigger may involve exposure to a pH between 2 and 7, a pH between 2.5 and 6.5, or a pH between 3 and 6. In another example, the (bio)chemical trigger may involve exposure to an alkaline pH. In one embodiment, the (bio)chemical trigger may involve exposure to a pH greater than 7, a pH greater than 7.5, a pH greater than 8, a pH greater than 8.5, a pH greater than 9, a pH greater than 9.5, a pH greater than 10, a pH greater than 10.5, or a pH greater than 11. In another embodiment, the (bio)chemical trigger may involve exposure to a pH between 9 and 14, a pH between 9.5 and 13.5, or a pH between 10 and 13.
[0325] Non-limiting examples of suitable deformable polymers may include poly(N-isopropylacrylamide) (PNiPAm), poly(N-isopropylmethacrylamide) (PNiPMAm), poly(acrylic acid) (PAAc), poly(methacrylic acid), poly(4-vinylpyridine) and / or poly(vinylamine). Therefore, in some embodiments, the deformable polymer may include poly(N-isopropylacrylamide) (PNiPAm), poly(N-isopropylmethacrylamide) (PNiPMAm), poly(acrylic acid) (PAAc), poly(methacrylic acid), poly(4-vinylpyridine) and / or poly(vinylamine); or may be a copolymer including poly(N-isopropylacrylamide) (PNiPAm), poly(N-isopropylmethacrylamide) (PNiPMAm), poly(acrylic acid) (PAAc), poly(methacrylic acid), poly(4-vinylpyridine) and / or poly(vinylamine).
[0326] In one embodiment, the first fixed primer and / or the second fixed primer can be attached to a deformable polymer by covalent bonds. In another embodiment, these covalent bonds can include cycloadducts, alkenylene bonds, esters, amides, acetals, hemiaminal ethers, aminals, imines, hydrazones, sulfide bonds, boronyl bonds, silicon-based bonds or phosphorus-based bonds. In another embodiment, the cycloadducts can include 1,2,3-triazole bonds.
[0327] In one embodiment, the deformable polymer may be composed of a plurality of particles. In another embodiment, the particles may be nanoparticles.
[0328] For example, the (average) particle size of nanoparticles may be between about 50nm and about 500nm. In other embodiments, the (average) particle size of nanoparticles may be between about 200nm and about 400nm. (Average) particle size may refer to the particle size measured at room temperature (25°C). Particle size analysis may be performed such as by light scattering to obtain relevant particle size distribution or Z average values.
[0329] In one embodiment, the deformable polymer may comprise a hydrogel.
[0330] In one embodiment, the deformable polymer may be a copolymer comprising a polymer responsive to a deformation trigger and a polymer that has formed a covalent bond with each of the first fixed primers and each of the second fixed primers. In another embodiment, the deformable polymer may be a copolymer comprising a polymer responsive to a deformation trigger and a polymer that has formed a cyclic adduct with each of the first fixed primers and each of the second fixed primers. In a further embodiment, the deformable polymer may be a copolymer comprising a polymer responsive to a deformation trigger and a polymer that has formed a 1,2,3-triazole bond with each of the first fixed primers and each of the second fixed primers.
[0331] In one embodiment, the deformable polymer may be formed from acrylamide-based monomers.
[0332] In one embodiment, the deformable polymer may be a copolymer comprising a polymer formed from an acrylamide monomer, a polymer responsive to a deformation trigger, and a polymer that has formed a covalent bond with each of the first fixed primers and each of the second fixed primers. In another embodiment, the deformable polymer may be a copolymer comprising a polymer formed from an acrylamide monomer, a polymer responsive to a deformation trigger, and a polymer that has formed a cyclic adduct with each of the first fixed primers and each of the second fixed primers. In a further embodiment, the deformable polymer may be a copolymer comprising a polymer formed from an acrylamide monomer, a polymer responsive to a deformation trigger, and a polymer that has formed a 1,2,3-triazole bond with each of the first fixed primers and each of the second fixed primers.
[0333] The deformable polymers as described herein can be used as surfaces or coatings on solid supports, in particular for nucleic acid sequencing.
[0334] Thus, in another aspect of the present invention there is provided a solid support comprising a deformable polymer as described herein.
[0335] In one embodiment, the solid support can be a flow cell.
[0336] As mentioned above, the deformable polymers and / or solid supports described herein can be used in nucleic acid sequencing, particularly concurrent sequencing.
[0337] Therefore, in another aspect of the present invention, there is provided use of a deformable polymer as described herein or a solid support as described herein in nucleic acid sequencing.
[0338] In another aspect of the present invention, there is provided a method for producing a deformable polymer, the method comprising:
[0339] (a) fixing a plurality of first precursor primers to a deformable polymer to form a plurality of first fixed primers; and
[0340] (b) immobilizing a plurality of second precursor primers to the deformable polymer to form a plurality of second immobilized primers;
[0341] Wherein the deformable polymer is configured such that when the deformable polymer is exposed to a deformation trigger, the plurality of first fixed primers and the second fixed primers are shifted to a second set of positions on the deformable polymer that is different from the first set of positions.
[0342] In one embodiment, the second precursor primer differs in sequence from the first precursor primer.
[0343] The deformable polymer to be manufactured may be a deformable polymer as described herein. Therefore, aspects related to the deformable polymer and other features of the deformable polymer as described herein are also applicable to the method for manufacturing the deformable polymer as described herein.
[0344] The term "first precursor primer" refers to the state of the first fixed primer of a solid support before being fixed to the solid support. Therefore, the first precursor primer can be provided as a "free" primer in a solution. After fixation, the "first precursor primer" is then referred to as the "first fixed primer".
[0345] The term "second precursor primer" refers to the state of the second fixed primer of the solid support before being fixed to the solid support. Therefore, the second precursor primer can be provided as a "free" primer in solution. After fixation, the "second precursor primer" is then referred to as the "second fixed primer".
[0346] Step (a) and step (b) may be performed sequentially or simultaneously.
[0347] For example, in one embodiment where step (a) and step (b) are performed sequentially, step (b) may be performed after step (a). Alternatively, step (a) may be performed after step (b).
[0348] In one embodiment, step (a) and step (b) may be performed simultaneously.
[0349] The immobilization method is not particularly limited, provided that the first immobilized primer and the second immobilized primer remain on the solid support during amplification, clustering and sequencing.
[0350] In one embodiment, immobilization can include forming covalent bonds between the solid support and each of the first precursor primers in the plurality of first precursor primers and between the solid support and each of the second precursor primers in the plurality of second precursor primers. In another embodiment, forming covalent bonds involves using a click reaction (e.g., a metal-catalyzed azide-alkyne cycloaddition reaction, such as a copper-catalyzed azide-alkyne cycloaddition reaction and a strain-promoted azide-alkyne cycloaddition).
[0351] Specifically, forming a covalent bond may involve forming a 1,2,3-triazole bond. The solid support before fixation may include an azide moiety (e.g., PAZAM), and the first precursor primer and the second precursor primer may each include an alkyne moiety (e.g., terminal alkyne, cycloalkyne). The click reaction between the azide moiety on the solid support and the alkyne moiety on the first precursor primer and the second precursor primer allows the formation of a 1,2,3-triazole bond. The configuration of the azide moiety and the alkyne moiety may also be exchanged, for example, by including an alkyne moiety on the solid support before fixation, and including an azide moiety on each of the first precursor primer and the second precursor primer.
[0352] The deformable polymers as described herein can be used in methods of preparing polynucleotide sequences for identification.
[0353] Therefore, in another aspect of the present invention, a method for preparing a polynucleotide sequence for identification is provided, the method comprising:
[0354] (a) providing a deformable polymer as described herein;
[0355] (b) synthesizing at least one first polynucleotide sequence and at least one second polynucleotide sequence, wherein the at least one first polynucleotide sequence each comprises a first portion and each extends from a first fixed primer, and the at least one second polynucleotide sequence each comprises a second portion and each extends from a second fixed primer, wherein the second polynucleotide sequence is substantially complementary to the first polynucleotide sequence.
[0356] "Identification" means obtaining genetic information from a polynucleotide chain here. This may include the identification of the genetic sequence of a polynucleotide chain (i.e., sequencing). In addition, this may alternatively or additionally include the identification of mismatched base pairs. In addition, this may alternatively or additionally include the identification of any epigenetic modification such as methylation. Therefore, "identification" may mean the identification of the genetic sequence of a polynucleotide chain, a mismatched base pair and / or the identification of any epigenetic modification.
[0357] In one embodiment, step (b) may involve synthesizing a plurality of first polynucleotide sequences, each of which comprises a first portion and each extends from a first fixed primer, and a plurality of second polynucleotide sequences, each of which comprises a second portion and each extends from a second fixed primer. Therefore, in one embodiment, a method for preparing a polynucleotide sequence for identification is provided, the method comprising:
[0358] (a) providing a deformable polymer as described herein;
[0359] (b) synthesizing a plurality of first polynucleotide sequences, each of which comprises a first portion and each extends from a first fixed primer, and a plurality of second polynucleotide sequences, each of which comprises a second portion and each extends from a second fixed primer, wherein the second polynucleotide sequence is substantially complementary to the first polynucleotide sequence.
[0360] The present invention is applicable to (separate) polynucleotide chains, wherein the first chain comprises a first portion to be identified and the second chain comprises a second portion to be identified.
[0361] The (separate) polynucleotide chain may comprise a first chain and a second chain, the first chain comprising a first portion that may comprise (or may be) a forward chain of a polynucleotide sequence (e.g., the forward chain of a template), the second chain comprising a second portion that may comprise (or may be) a reverse chain of the polynucleotide sequence (e.g., the reverse chain of the template) or a forward complementary chain of the polynucleotide sequence (e.g., the forward complementary chain of the template). As another alternative, the (separate) polynucleotide chain may comprise a first chain and a second chain, the first chain comprising a first portion that may comprise (or may be) a reverse chain of a polynucleotide sequence (e.g., the reverse chain of the template), the second chain comprising a second portion that may comprise (or may be) a forward chain of the polynucleotide sequence (e.g., the forward chain of the template) or a reverse complementary chain of the polynucleotide sequence (e.g., the reverse complementary chain of the template).
[0362] Since the forward strand and the reverse strand (or the forward strand and the forward complementary strand or the reverse strand and the reverse complementary strand) are substantially complementary to each other, these strands tend to self-hybridize. Considering the use of a deformable polymer, wherein the deformable polymer is constructed so that when the deformable polymer is exposed to a deformation trigger, a plurality of first fixed primers and a second fixed primer are shifted to a second group of positions different from the first group of positions on the deformable polymer, and once the deformable polymer is exposed to a deformation trigger, the deformable primer is in a state ready to separate these self-hybridization structures. Therefore, this makes these chains single-stranded and available for initiation and sequencing.
[0363] The first portion may be referred to herein as read 1 (R1). The second portion may be referred to herein as read 2 (R2).
[0364] In one embodiment, the first portion is at least 25 or at least 50 base pairs and the second portion is at least 25 base pairs or at least 50 base pairs.
[0365] The deformable polymer can be disposed on a solid support (e.g., on the surface of the solid support). In another embodiment, the solid support can be a flow cell. In another embodiment, each of the first chain and the second chain is located in a single hole of the solid support.
[0366] The polynucleotide chains may form a cluster or be part of a cluster on the solid support.
[0367] As used herein, the term "cluster" may refer to a (substantially) clonal group of template polynucleotides (e.g., DNA or RNA) incorporated in a single hole of a solid support (e.g., a flow cell). Therefore, a cluster may refer to a colony of polynucleotide molecules subsequently sequenced in a hole."cluster" may contain a sufficient number of copies of template polynucleotides so that the cluster can output a signal (e.g., an optical signal) that allows the cluster to be sequenced and read. "Cluster" may include, for example, about 500 to about 2000 copies, about 600 to about 1800 copies, about 700 to about 1600 copies, about 800 to about 1400 copies, about 900 to about 1200 copies, or about 1000 copies of template polynucleotides.
[0368] As described above, clusters can be formed by bridge amplification.
[0369] The clusters formed may be biclonal clusters.
[0370] A "double clone" cluster means that the population of polynucleotide sequences that are subsequently sequenced (as a next step) is essentially of two types - for example, a first sequence and a second sequence. Thus, a "double clone" cluster can refer to a population of a single first sequence and a single second sequence that are subsequently sequenced in a well. A "double clone" cluster can contain a sufficient number of copies of a single first sequence and a sufficient number of copies of a single second sequence so that the cluster can output a signal (e.g., an optical signal) that allows a "monoclonal" cluster to be sequenced and read. A "double clone" cluster can contain, for example, about 500 to about 2000 combined copies, about 600 to about 1800 combined copies, about 700 to about 1600 combined copies, about 800 to about 1400 combined copies, about 900 to about 1200 combined copies, or about 1000 combined copies of a single first sequence and a single second sequence. The copies of a single first sequence and a single second sequence together may comprise at least about 50%, at least about 60%, at least about 70%, even at least about 80%, at least about 90%, or about 95%, 98%, 99% or 100% of all the polynucleotides within a single well of the flow cell, thereby providing an essentially biclonal "cluster."
[0371] The method may further comprise the step of preparing the first part and the second part for concurrent sequencing.
[0372] For example, the method may include simultaneously contacting a first sequencing primer binding site located behind the 3' end of the first portion with a first primer, and contacting a second sequencing primer binding site located behind the 3' end of the second portion with a second primer. Thus, the first portion and the second portion are primed for concurrent sequencing.
[0373] In some embodiments, the method may include the following steps: processing at least one first polynucleotide sequence comprising a first portion and at least one second polynucleotide sequence comprising a second portion so that a certain proportion of the first portion is capable of generating a first signal and a certain proportion of the second portion is capable of generating a second signal.
[0374] In some embodiments, the first signal and the second signal can be spatially resolved. In other embodiments, the first signal and the second signal cannot be spatially resolved.
[0375] In some embodiments (e.g., where spatially resolvable signals are used), a proportion of the first portion can generate a first signal and a proportion of the second portion can generate a second signal, wherein the intensity of the first signal is substantially the same as the intensity of the second signal.
[0376] In other embodiments (e.g., where selective processing methods are used as described herein), a proportion of the first portion can generate a first signal and a proportion of the second portion can generate a second signal, wherein the selective processing causes the intensity of the first signal to be greater than the intensity of the second signal. The first signal and the second signal cannot be spatially resolved (e.g., are generated from the same area or substantially overlapping areas).
[0377] Other aspects related to selective processing methods (eg, performing selective amplification, performing selective sequencing, or preparing for selective sequencing) have been described herein and are applicable to methods of preparing polynucleotide sequences for identification as described herein.
[0378] In one embodiment, the method may further comprise the following steps:
[0379] (c) exposing the deformable polymer to a deformation trigger.
[0380] Step (c) of exposing the deformable polymer to a deformation trigger may be performed after step (b) of synthesizing at least one first polynucleotide sequence and at least one second polynucleotide sequence, wherein the at least one first polynucleotide sequence each comprises a first portion and each extends from a first fixed primer, and the at least one second polynucleotide sequence each comprises a second portion and each extends from a second fixed primer.
[0381] By actuating the deformable primer when exposed to a deformation trigger, this causes the first and second fixed primers to shift from a first set of positions to a second set of positions. Thus, the first and second polynucleotide sequences are also physically moved, thereby separating any self-hybridizing structures.
[0382] As mentioned above, the type of shifting is not particularly limited, provided that the second set of positions is different from the first set of positions.
[0383] In one embodiment, the deformation trigger may cause expansion of the deformable polymer.
[0384] In another embodiment, the deformation trigger may cause contraction of the deformable polymer.
[0385] In other embodiments, the deformation trigger may cause expansion and then contraction of the deformable polymer, or contraction and then expansion of the deformable polymer. For example, the deformation trigger may involve more than one change in reaction conditions, such as heating and then cooling, cooling and then heating, exposure to high salt concentration and then low salt concentration, exposure to lower pH and then higher pH, exposure to higher pH and then lower pH, etc. Different types of deformation triggers may also be combined, such as temperature changes, salt concentration changes, and pH changes.
[0386] As described above, causing expansion and then contraction (or contraction and then expansion) in this manner can cause shuffling of the first and second immobilized primers.
[0387] Suitable types of deformation triggers (e.g., physical triggers and / or (bio)chemical triggers, such as temperature changes, changes in salt concentration or pH changes) are described herein with reference to deformable polymers, and the same applies to the types of deformation triggers that can be used in the methods for preparing polynucleotide sequences for identification as described herein.
[0388] Sequencing methods
[0389] Also described herein is a method for sequencing a polynucleotide sequence, the method comprising preparing a polynucleotide sequence for identification using a method as described herein; and sequencing the nucleobases in the first portion and the second portion.
[0390] In one embodiment, the step of sequencing the nucleobases in the first portion and the second portion may involve concurrently sequencing the nucleobases in the first portion and the second portion.
[0391] In one embodiment, sequencing can be performed by sequencing by synthesis or sequencing by ligation.
[0392] In one embodiment, the method may further comprise the step of performing paired end reading.
[0393] In some embodiments, the data may be analyzed using 16QAM as mentioned herein.
[0394] Thus, the steps of concurrently sequencing the nucleobases may include:
[0395] (a) obtaining first intensity data, the first intensity data comprising a combined intensity of a first signal component obtained based on a corresponding first nucleobase at a first portion and a second signal component obtained based on a corresponding second nucleobase at a second portion, wherein the first signal component and the second signal component are obtained simultaneously;
[0396] (b) obtaining second intensity data, the second intensity data comprising a combined intensity of a third signal component obtained based on the corresponding first nucleobase at the first portion and a fourth signal component obtained based on the corresponding second nucleobase at the second portion, wherein the third signal component and the fourth signal component are obtained simultaneously;
[0397] (c) selecting one of a plurality of categories based on the first intensity data and the second intensity data, wherein each category represents a possible combination of a corresponding first nucleobase and a corresponding second nucleobase; and
[0398] (d) base calling the corresponding first nucleobase and the corresponding second nucleobase based on the selected classification.
[0399] In one embodiment, selecting the classification based on the first intensity data and the second intensity data may include selecting the classification based on a combined intensity of the first signal component and the second signal component and a combined intensity of the third signal component and the fourth signal component.
[0400] In one embodiment, the plurality of categories can include sixteen categories, each category representing one of sixteen unique combinations of a first nucleobase and a second nucleobase.
[0401] In one embodiment, the first signal component, the second signal component, the third signal component, and the fourth signal component can be generated based on light emissions associated with the corresponding nucleobases.
[0402] In one example, the light emission may be detected by a sensor, wherein the sensor is configured to provide a single output based on the first signal and the second signal.
[0403] In one embodiment, the sensor may include a single sensing element.
[0404] In one embodiment, the method may further comprise repeating steps (a) to (d) for each base calling cycle in a plurality of base calling cycles.
[0405] Reagent test kit
[0406] The method described herein can be physically performed by a user. In other words, a user can perform the method of preparing a polynucleotide sequence for identification as described herein by himself, and thus the method described herein may not require computer implementation.
[0407] In another aspect of the present invention, a kit is provided, the kit comprising a deformable polymer as described herein or a solid support as described herein.
[0408] In another aspect of the present invention, a kit is provided, the kit comprising instructions for preparing a polynucleotide sequence for identification according to the methods described herein and / or sequencing a polynucleotide sequence according to the methods described herein.
[0409] Computer programs and products
[0410] In other embodiments, the method as described herein can be performed by a computer. In other words, a computer can contain instructions for performing the method of preparing a polynucleotide sequence for identification as described herein, and thus the method as described herein can be implemented by a computer.
[0411] Therefore, in another aspect of the present invention, there is provided a data processing apparatus comprising means for performing a method as described herein.
[0412] The data processing device may be a polynucleotide sequencer.
[0413] The data processing apparatus may include reagents for use in the methods as described herein.
[0414] The data processing device may comprise a solid support as described herein, such as a flow cell.
[0415] In another aspect of the present invention, a computer program product is provided, the computer program product comprising instructions, which, when the program is executed by a processor, cause the processor to perform the method as described herein.
[0416] In another aspect of the present invention, a computer-readable storage medium is provided. The computer-readable storage medium includes instructions. When the instructions are executed by a processor, the processor is caused to perform the method as described herein.
[0417] In another aspect of the present invention, a computer readable data carrier is provided, on which a computer program product as described herein is stored.
[0418] In another aspect of the invention, there is provided a data carrier signal carrying a computer program product as described herein.
[0419] Various exemplary imaging or data processing techniques described in conjunction with the embodiments disclosed herein can be implemented as electronic hardware, computer software, or a combination of the two. To illustrate this interchangeability of hardware and software, various exemplary components, blocks, modules, and steps have been described above in general terms with respect to their functionality. Whether this functionality is implemented as hardware or software depends on the specific application and the design constraints imposed on the entire system. The described functionality can be implemented in different ways for each specific application, but such implementation decisions should not be interpreted as causing a departure from the scope of the present disclosure.
[0420] The various exemplary detection systems described in conjunction with the embodiments disclosed herein may be implemented or executed by a machine designed to perform the functions described herein, such as a processor configured with specific instructions, a digital signal processor (DSP), an application specific integrated circuit (ASIC), a field programmable gate array (FPGA) or other programmable logic device, a discrete gate or transistor logic component, a discrete hardware component, or any combination thereof. The processor may be a microprocessor, but in an alternative, the processor may be a controller, a microcontroller or a state machine, a combination thereof, or the like. The processor may also be implemented as a combination of computing devices, for example, a combination of a DSP and a microprocessor, a plurality of microprocessors, one or more microprocessors combined with a DSP core, or any other such configuration. For example, the systems described herein may be implemented using discrete memory chips, a portion of a memory in a microprocessor, flash memory, EPROM, or other types of memory.
[0421] The elements of the methods, processes or algorithms described in conjunction with the embodiments disclosed herein can be directly implemented in hardware, in software modules executed by a processor, or in a combination of the two. The software module can reside in a RAM memory, a flash memory, a ROM memory, an EPROM memory, an EEPROM memory, a register, a hard disk, a removable disk, a CD-ROM, or any other form of computer-readable storage medium known in the art. An exemplary storage medium can be coupled to a processor so that the processor can read information from the storage medium and write information thereto. In an alternative, the storage medium can be integral with the processor. The processor and the storage medium can reside in an ASIC. The software module can include computer executable instructions that cause a hardware processor to execute computer executable instructions.
[0422] Computer-executable instructions may be stored in a (transitory or non-transitory) computer-readable storage medium (eg, memory, storage system, etc.) that stores code or computer-readable instructions.
[0423] Additional Notes
[0424] The embodiments described herein are exemplary. These embodiments may be modified, rearranged, alternatively processed, etc., and these are still encompassed within the teachings set forth herein. One or more of the steps, processes, or methods described herein may be performed by one or more processing devices and / or digital devices that are appropriately programmed.
[0425] Unless otherwise specifically stated or understood in the context of use, conditional language used herein such as "can", "may", "could", "for example", etc. is generally intended to convey that certain embodiments include, while other embodiments do not include certain features, elements and / or states. Therefore, such conditional language is generally not intended to imply that features, elements and / or states are necessary for one or more embodiments in any way, nor is it intended to imply that one or more embodiments necessarily include logic for determining whether these features, elements and / or states are included in any particular embodiment or to be performed in any particular embodiment with or without author input or prompting. The terms "include", "comprise", "have", "involve", etc. are synonyms, used inclusively in an open manner, and do not exclude additional elements, features, actions, operations, and the like. Moreover, the term "or" is used in its inclusive sense (rather than in its exclusive sense), so that when, for example, it is used to connect a list of elements, the term "or" means one, some or all of the elements in the list. The term "comprising" may be considered to cover "consisting of".
[0426] Unless specifically stated otherwise or otherwise understood in the context in which it is generally used to refer to an item, term, etc., disjunctive language such as the phrase "at least one of X, Y, or Z" can be X, Y, or Z, or any combination thereof (e.g., X, Y, and / or Z). Thus, such disjunctive language is generally not intended to, and should not, imply that certain embodiments require that at least one of X, at least one of Y, or at least one of Z each be present.
[0427] The terms "about" or "approximately" and the like are synonymous and are used to indicate that the value modified by the term has an understanding range associated therewith, where the range may be ±20%, ±15%, ±10%, ±5%, or ±1%. The term "substantially" is used to indicate that a result (e.g., a measured value) is close to a target value, where "close" may mean, for example, that the result is within 80% of the value, within 90% of the value, within 95% of the value, or within 99% of the value. The term "partially" is used to indicate that an effect is only partially or to a limited extent.
[0428] Unless expressly stated otherwise, articles such as "a" or "an" should generally be interpreted as including one or more of the described items. Thus, phrases such as "a device configured to" or "a device for" are intended to include one or more of the recited devices. Such one or more of the described devices may also be collectively configured to perform the stated statements. For example, "a processor for performing statements A, B, and C" may include a first processor configured to perform statement A and working in conjunction with a second processor configured to perform statement B and statement C.
[0429] Although the above detailed description has shown, described and pointed out the novel features applied to the exemplary embodiments, it should be understood that various omissions, substitutions and changes in the form and details of the illustrated devices or algorithms can be made without departing from the essence of the present disclosure. As will be appreciated, certain embodiments described herein can be embodied in a form that does not provide all of the features and benefits set forth herein, as some features can be used or practiced separately from other features. All changes that come within the meaning and range of equivalency of the claims are to be included within their scope.
[0430] It should be understood that all combinations of the aforementioned concepts (assuming such concepts are not mutually contradictory) are contemplated as being part of the inventive subject matter disclosed herein. In particular, all combinations of the claimed subject matter appearing at the end of this disclosure are contemplated as being part of the inventive subject matter disclosed herein.
[0431] The invention will now be described by way of the following non-limiting examples.
[0432] Example
[0433] Example 1: Study on the influence of different amplifications on the self-hybridization ability of forward and reverse strands
[0434] The polymer usually behaves as a randomly coiled spaghetti ball whose size is determined by the persistence length of the molecule. Some simple estimates of the work of extension of the polymer can be made by using the new expansion distance. See the calculation results in the table below. The work of extension can be used to estimate the probability that a DNA molecule will spontaneously extend to this distance and bind to its complementary strand. As can be seen in the table below, this probability decreases greatly with expansion.
[0435] 3× Expansion 2× Expansion 1.5× expansion Nanopore size 400 400 400 nm #DNA molecule 500 500 500 count Average spacing 17.9 17.9 17.9 nm
[0436]
[0437] Under low tension, ssDNA behaves roughly like a Hooke's spring described by the following equation:
[0438]
[0439] For a system in equilibrium in a canonical ensemble, the probability that the system is in a state with energy E is related to e -ΔE / kT Proportional.
[0440] Example 2: Synthesis of P5 / P7 grafted nanogel
[0441] Synthesis of azide-containing polymer particles. The particles were synthesized using suspension polymerization in an aqueous medium. Sodium dodecyl sulfate (SDS) was used as an anionic surfactant. In a typical procedure, a monomer mixture consisting of N-isopropylacrylamide, acrylic acid, N-(5-(2-azidoacetamido)pentyl)acrylamide and N,N′-methylenebisacrylamide was added to deionized water in a reaction flask, followed by the addition of SDS. The mixture was degassed under nitrogen at 70°C, followed by the addition of a free radical initiator (ammonium persulfate). The reaction was carried out under nitrogen at 70°C. At the end of the reaction, the mixture was exposed to air and quenched in an ice bath. The particles were purified using dialysis against deionized water with a molecular weight cutoff (MWCO) of 14,000 Da.
[0442] Synthesis of P5 / P7 grafted nanogels. P5 / P7 primers were grafted onto the particles using a strain-promoted azide-alkyne cycloaddition reaction between (1R,8S,9S)-bicyclo[6.1.0]nonyne (BCN) and an azido group (N3). P5 / P7 containing BCN end groups was added to a solution of nanogel particles. The reaction was carried out at room temperature for 18 hours. The particles were purified using dialysis against deionized water with a molecular weight cutoff (MWCO) of 14,000 Da.
[0443] Further examples are described in US 63 / 407,852, the contents of which are incorporated herein by reference.
[0444] Sequence Listing
[0445] SEQ ID NO.1: P5 sequence
[0446] AATGATACGGCGACCACCGAGATCTACAC
[0447] SEQ ID NO.2: P7 sequence
[0448] CAAGCAGAAGACGGCATACGAGAT
[0449] SEQ ID NO.3: P5′ sequence (complementary to P5)
[0450] GTGTAGATCTCGGTGGTCGCCGTATCATT
[0451] SEQ ID NO.4: P7′ sequence (complementary to P7)
[0452] ATCTCGTATGCCGTCTTCTGCTTG
[0453] SEQ ID NO.5: Alternative P5 sequence
[0454] AATGATACGGCGACCGA
[0455] SEQ ID NO.6: Alternative P5′ sequence (complementary to the alternative P5 sequence)
[0456] TCGGTCGCCGTATCATT
[0457] SEQ ID NO.7: SBS3
[0458] ACACTCTTTCCCTACACGACCGCTTCCGATCT
[0459] SEQ ID NO.8: SBS3′
[0460] AGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGT
[0461] SEQ ID NO.9: SBS12
[0462] GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT
[0463] SEQ ID NO.10: SBS12′
[0464] AGATCGGAAGAGCACACGTCTGAACTCCAGTCAC
[0465] SEQ ID NO.11: Removable P5 sequence
[0466] TTTTTTTTTTAATGATACGGCGACCACCGAUCTACAC
[0467] (where U = 2-deoxyuridine)
[0468] SEq ID NO.12: Removable P7 sequence
[0469] TTTTTTTTTTCAAGCAGAAGACGGCATACGA[G 氧代 ]AT
[0470] (where [G 氧代 ]=8-oxoguanine)
[0471] SEQ ID NO.13: Extension primer sequence with A as the additional 5′ nucleotide and having a P5′ sequence (complementary to P5)
[0472] AGTGTAGATCTCGGTGGTCGCCGTATCATT
[0473] SEQ ID NO.14: Extension primer sequence with T as the additional 5′ nucleotide and P5′ sequence (complementary to P5)
[0474] TGTGTAGATCTCGGTGGTCGCCGTATCATT
[0475] SEQ ID NO.15: Extension primer sequence with C as the additional 5′ nucleotide and having a P5′ sequence (complementary to P5)
[0476] CGTGTAGATCTCGGTGGTCGCCGTATCATT
[0477] SEQ ID NO.16: Extension primer sequence with G as the additional 5′ nucleotide and P5′ sequence (complementary to P5)
[0478] GGTGTAGATCTCGGTGGTCGCCGTATCATT
[0479] SEQ ID NO.17: Extension primer sequence with A as the additional 5′ nucleotide and P7′ sequence (complementary to P7)
[0480] AATCTCGTATGCCGTCTTCTGCTTG
[0481] SEQ ID NO.18: Extension primer sequence with T as the additional 5′ nucleotide and P7′ sequence (complementary to P7)
[0482] TATCTCGTATGCCGTCTTCTGCTTG
[0483] SEQ ID NO.19: Extension primer sequence with C as the additional 5′ nucleotide and P7′ sequence (complementary to P7)
[0484] CATCTCGTATGCCGTCTTCTGCTTG
[0485] SEQ ID NO.20: Extension primer sequence with G as the additional 5′ nucleotide and P7′ sequence (complementary to P7)
[0486] GATCTCGTATGCCGTCTTCTGCTTG
[0487] SEQ ID NO.21: Extension primer sequence with A as additional 5′ nucleotide and having alternative P5′ sequence (complementary to alternative P5)
[0488] ATCGGTCGCCGTATCATT
[0489] SEQ ID NO.22: Extension primer sequence with T as the additional 5′ nucleotide and having an alternative P5′ sequence (complementary to alternative P5)
[0490] TTCGGTCGCCGTATCATT
[0491] SEQ ID NO.23: Extension primer sequence with C as the additional 5′ nucleotide and having an alternative P5′ sequence (complementary to alternative P5)
[0492] CTCGGTCGCCGTATCATT
[0493] SEQ ID NO.24: Extension primer sequence with G as the additional 5′ nucleotide and having an alternative P5′ sequence (complementary to alternative P5)
[0494] GTCGGTCGCCGTATCATT
Claims
1. A deformable polymer, comprising: a first plurality of immobilized primers; and a plurality of second fixed primers, wherein the plurality of first fixed primers and the plurality of second fixed primers occupy a first set of positions on the deformable polymer, The deformable polymer is configured such that when the deformable polymer is exposed to a deformation trigger, the plurality of first immobilized primers and the second immobilized primers are displaced to a second set of locations on the deformable polymer that is different from the first set of locations.
2. The deformable polymer of claim 1, wherein the deformation trigger causes a volume expansion of the deformable polymer.
3. The deformable polymer of claim 2, wherein the expansion is at least a 20% volume increase, at least a 50% volume increase, or at least a 100% volume increase.
4. The deformable polymer of claim 1, wherein the deformation trigger causes a volume contraction of the deformable polymer.
5. The deformable polymer of claim 4, wherein the shrinkage is a volume reduction of at least 20%, a volume reduction of at least 50%, or a volume reduction of at least 100%.
6. The deformable polymer according to any one of claims 1 to 5, wherein the deformation triggers a shuffling of the first and second immobilized primers.
7. A deformable polymer according to claim 6, wherein the reorganization is accompanied by a 20% volume reduction to a 20% volume increase of the deformable polymer, a 10% volume reduction to a 10% volume increase of the deformable polymer or a 5% volume reduction to a 5% volume increase of the deformable polymer.
8. The deformable polymer according to any one of claims 1 to 7, wherein the deformation trigger is a physical trigger and / or a (bio)chemical trigger.
9. A deformable polymer according to claim 8, wherein the physical trigger comprises a temperature change of the deformable polymer, wherein the (bio)chemical trigger comprises a salt concentration change, or wherein the (bio)chemical trigger comprises a pH change.
10. The deformable polymer according to any one of claims 1 to 9, wherein the first immobilized primer and / or the second immobilized primer are attached to the deformable polymer by a covalent bond.
11. The deformable polymer of claim 10, wherein the covalent bond comprises a cycloadduct, an alkenylene bond, an ester, an amide, an acetal, a hemiaminal ether, an aminal, an imine, a hydrazone, a sulfide bond, a boron-based bond, a silicon-based bond, or a phosphorus-based bond.
12. The deformable polymer of claim 11, wherein the cycloadduct comprises a 1,2,3-triazole bond.
13. The deformable polymer according to any one of claims 1 to 12, wherein the deformable polymer is composed of a plurality of particles.
14. A solid support comprising the deformable polymer according to any one of claims 1 to 13.
15. A kit comprising the deformable polymer according to any one of claims 1 to 13 or the solid support according to claim 14.
16. A method of making a deformable polymer, the method comprising: (a) fixing a plurality of first precursor primers to a deformable polymer to form a plurality of first fixed primers; as well as (b) fixing a plurality of second precursor primers to the deformable polymer to form a plurality of second fixed primers; The deformable polymer is configured such that when the deformable polymer is exposed to a deformation trigger, the plurality of first immobilized primers and the second immobilized primers are displaced to a second set of locations on the deformable polymer that is different from the first set of locations.
17. The method according to claim 16, wherein step (a) and step (b) are performed sequentially or simultaneously.
18. A method according to claim 16 or claim 17, wherein step (b) is performed after step (a), wherein step (a) is performed after step (b), or wherein step (a) and step (b) are performed simultaneously.
19. The method of any one of claims 16 to 18, wherein immobilizing comprises forming covalent bonds between the solid support and each first precursor primer in the plurality of first precursor primers and between the solid support and each second precursor primer in the plurality of second precursor primers.
20. The method of claim 19, wherein forming the covalent bond involves using a click reaction.
21. A method according to claim 19 or claim 20, wherein forming a covalent bond involves forming a 1,2,3-triazole bond.
22. A method for preparing a polynucleotide sequence for identification, the method comprising: (a) providing a deformable polymer according to any one of claims 1 to 13; (b) synthesizing at least one first polynucleotide sequence and at least one second polynucleotide sequence, The at least one first polynucleotide sequence each comprises a first portion and each extends from a first fixed primer, and the at least one second polynucleotide sequence each comprises a second portion and each extends from a second fixed primer, wherein the second polynucleotide sequence is substantially complementary to the first polynucleotide sequence.
23. The method according to claim 22, wherein the method further comprises the following steps: (c) exposing the deformable polymer to a deformation trigger.
24. A method according to claim 22 or claim 23, wherein the deformation trigger causes expansion of the deformable polymer, wherein the deformation trigger causes contraction of the deformable polymer, wherein the deformation trigger causes expansion and then contraction of the deformable polymer, or contraction and then expansion of the deformable polymer.
25. The method according to any one of claims 22 to 24, wherein the deformation trigger is a physical trigger and / or a (bio)chemical trigger.
26. The method of claim 25, wherein the physical trigger comprises a change in temperature of the deformable polymer, wherein the (bio)chemical trigger comprises a change in salt concentration, or wherein the (bio)chemical trigger comprises a change in pH.
27. The method according to any one of claims 22 to 26, wherein the method further comprises the following steps: The first part and the second part are prepared for concurrent sequencing.
28. The method of any one of claims 22 to 27, wherein the method comprises simultaneously contacting a first sequencing primer binding site located after the 3' end of the first portion with a first primer, and contacting a second sequencing primer binding site located after the 3' end of the second portion with a second primer.
29. The method according to any one of claims 22 to 28, wherein the method further comprises the following steps: The at least one first polynucleotide sequence comprising a first portion and the at least one second polynucleotide sequence comprising a second portion are processed such that a proportion of the first portion is capable of generating a first signal and a proportion of the second portion is capable of generating a second signal.
30. The method of claim 29, wherein the processing involves selective processing to cause the strength of the first signal to be greater than the strength of the second signal.
31. The method of claim 30, wherein a concentration of the first portion capable of generating the first signal is greater than a concentration of the second portion capable of generating the second signal.
32. A method according to claim 31, wherein the ratio between the concentration of the first part capable of generating the first signal and the concentration of the second part capable of generating the second signal is between 1.25:1 and 5:1, wherein the ratio is between 1.5:1 and 3:1, or wherein the ratio is about 2:
1.
33. The method of any one of claims 30 to 32, wherein the selective processing comprises preparing for selective sequencing or performing selective sequencing.
34. The method of any one of claims 30 to 32, wherein the selective processing comprises performing selective amplification.
35. The method of any one of claims 30 to 33, wherein the selective treatment comprises contacting a first sequencing primer binding site located after the 3′ end of the first portion with a first primer, and contacting a second sequencing primer binding site located after the 3′ end of the second portion with a second primer, wherein the second primer comprises a mixture of a blocked second primer and an unblocked second primer.
36. The method of claim 35, wherein the blocked second primer comprises a blocking group at the 3' end of the blocked second primer.
37. A method according to any one of claims 30 to 32 or 34, wherein the selective treatment comprises selectively removing some or substantially all of the second fixed primers that have not been extended, and performing further amplification cycles to selectively amplify the first polynucleotide sequence relative to the second polynucleotide sequence.
38. A method according to any one of claims 30 to 32 or 34, wherein the selective treatment includes selectively blocking some or substantially all of the second fixed primers that have not yet been extended using a primer blocking agent, wherein the primer blocking agent is constructed to limit or prevent the synthesis of a chain extending from the second fixed primer, and performing further amplification cycles to selectively amplify the first polynucleotide sequence relative to the second polynucleotide sequence.
39. The method of claim 38, wherein the primer blocking agent is added while the first polynucleotide sequence is hybridized to the second immobilized primer.
40. The method of claim 38, wherein the method comprises contacting some or substantially all of the second fixed primers with an extension primer sequence, wherein the extension primer sequence is substantially complementary to the second fixed primer and further comprises an additional 5′ nucleotide; and adding the primer capping agent, wherein the primer capping agent is complementary to the additional 5′ nucleotide.
41. The method of any one of claims 38 to 40, wherein the primer blocking agent is a blocked nucleotide.
42. The method of claim 41, wherein the blocked nucleotide comprises a blocking group at the 3' end of the blocked nucleotide.
43. The method of claim 41 or claim 42, wherein the blocked nucleotide is A or G.
44. The method of any one of claims 22 to 43, wherein the first signal and the second signal are spatially resolved, or wherein the first signal and the second signal are not spatially resolved.
45. A method for sequencing a polynucleotide sequence, the method comprising: Prepare a polynucleotide sequence for identification using the method according to any one of claims 22 to 44; as well as The nucleobases in the first portion and the second portion are sequenced.
46. The method of claim 45, wherein the step of sequencing the nucleobases in the first portion and the second portion involves concurrently sequencing the nucleobases in the first portion and the second portion.
47. The method of claim 45 or claim 46, wherein the step of sequencing the nucleobases comprises performing sequencing by synthesis or sequencing by ligation.
48. A kit comprising instructions for preparing a polynucleotide sequence for identification according to any one of claims 22 to 44 and / or for sequencing a polynucleotide sequence according to any one of claims 45 to 47.
49. Data processing apparatus comprising means for performing a method according to any one of claims 22 to 47.
50. A computer program product comprising instructions which, when executed by a processor, cause the processor to perform the method according to any one of claims 22 to 47.
51. A computer-readable storage medium comprising instructions which, when executed by a processor, cause the processor to perform the method according to any one of claims 22 to 47.
52. A computer-readable data carrier having stored thereon a computer program product according to claim 50.
53. A data carrier signal carrying a computer program product according to claim 50.
